
<html lang="en"     class="pb-page"  data-request-id="548d6729-08c2-4f61-8440-eb8623f4d90d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-3;article:article:10.1021/acs.jmedchem.6b00871;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension" /></meta><meta name="dc.Creator" content="Thuy-Anh  Tran" /></meta><meta name="dc.Creator" content="Bryan  Kramer" /></meta><meta name="dc.Creator" content="Young-Jun  Shin" /></meta><meta name="dc.Creator" content="Pureza  Vallar" /></meta><meta name="dc.Creator" content="P. Douglas  Boatman" /></meta><meta name="dc.Creator" content="Ning  Zou" /></meta><meta name="dc.Creator" content="Carleton R.  Sage" /></meta><meta name="dc.Creator" content="Tawfik  Gharbaoui" /></meta><meta name="dc.Creator" content="Ashwin  Krishnan" /></meta><meta name="dc.Creator" content="Biman  Pal" /></meta><meta name="dc.Creator" content="Sagar R.  Shakya" /></meta><meta name="dc.Creator" content="Antonio  Garrido Montalban" /></meta><meta name="dc.Creator" content="John W.  Adams" /></meta><meta name="dc.Creator" content="Juan  Ramirez" /></meta><meta name="dc.Creator" content="Dominic P.  Behan" /></meta><meta name="dc.Creator" content="Anna  Shifrina" /></meta><meta name="dc.Creator" content="Anthony  Blackburn" /></meta><meta name="dc.Creator" content="Tina  Leakakos" /></meta><meta name="dc.Creator" content="Yunqing  Shi" /></meta><meta name="dc.Creator" content="Michael  Morgan" /></meta><meta name="dc.Creator" content="Abu  Sadeque" /></meta><meta name="dc.Creator" content="Weichao  Chen" /></meta><meta name="dc.Creator" content="David J.  Unett" /></meta><meta name="dc.Creator" content="Ibragim  Gaidarov" /></meta><meta name="dc.Creator" content="Xiaohua  Chen" /></meta><meta name="dc.Creator" content="Steve  Chang" /></meta><meta name="dc.Creator" content="Hsin-Hui  Shu" /></meta><meta name="dc.Creator" content="Shiu-Feng  Tung" /></meta><meta name="dc.Creator" content="Graeme  Semple" /></meta><meta name="dc.Description" content="The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are describe..." /></meta><meta name="Description" content="The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are describe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 19, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00871" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00871" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00871" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00871" /></link>
        
    
    

<title>Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00871" /></meta><meta property="og:title" content="Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0005.jpeg" /></meta><meta property="og:description" content="The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described. Detailed profiling of a number of analogues resulted in the identification of 5c (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor. In our hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clinical compound NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays. 5c had an excellent PK profile across species. Enterohepatic recirculation most probably contributes to a concentration–time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio. Following the identification of an acceptable solid form, 5c was selected for further development for the treatment of PAH." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00871"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00871">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00871&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00871&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00871&amp;href=/doi/10.1021/acs.jmedchem.6b00871" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 913-927</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00795" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01075" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thuy-Anh++Tran">Thuy-Anh Tran</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan++Kramer">Bryan Kramer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Young-Jun++Shin">Young-Jun Shin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pureza++Vallar">Pureza Vallar</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=P.+Douglas++Boatman">P. Douglas Boatman</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Zou">Ning Zou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carleton+R.++Sage">Carleton R. Sage</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tawfik++Gharbaoui">Tawfik Gharbaoui</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ashwin++Krishnan">Ashwin Krishnan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Biman++Pal">Biman Pal</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sagar+R.++Shakya">Sagar R. Shakya</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antonio++Garrido+Montalban">Antonio Garrido Montalban</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+W.++Adams">John W. Adams</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Ramirez">Juan Ramirez</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dominic+P.++Behan">Dominic P. Behan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Shifrina">Anna Shifrina</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Blackburn">Anthony Blackburn</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tina++Leakakos">Tina Leakakos</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yunqing++Shi">Yunqing Shi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Morgan">Michael Morgan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Abu++Sadeque">Abu Sadeque</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weichao++Chen">Weichao Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+J.++Unett">David J. Unett</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ibragim++Gaidarov">Ibragim Gaidarov</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohua++Chen">Xiaohua Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Chang">Steve Chang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hsin-Hui++Shu">Hsin-Hui Shu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shiu-Feng++Tung">Shiu-Feng Tung</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Graeme++Semple">Graeme Semple</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-9666-1588" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Current address: Beacon Discovery Inc., 6118 Nancy Ridge Drive, San Diego, CA 92121, U.S. Phone: +1 (858) 247-0001. E-mail: <a href="/cdn-cgi/l/email-protection#492e3a2c2439252c092b2c282a26272d203a2a263f2c3b30672a2624"><span class="__cf_email__" data-cfemail="751206101805191035171014161a1b111c06161a0310070c5b161a18">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00871&amp;href=/doi/10.1021%2Facs.jmedchem.6b00871" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 913–927</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 10, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 June 2016</li><li><span class="item_label"><b>Published</b> online</span>19 January 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 February 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00871" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00871</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D913%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DThuy-Anh%2BTran%252C%2BBryan%2BKramer%252C%2BYoung-Jun%2BShin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D3%26contentID%3Dacs.jmedchem.6b00871%26title%3DDiscovery%2Bof%2B2-%2528%2528%25281r%252C4r%2529-4-%2528%2528%25284-Chlorophenyl%2529%2528phenyl%2529carbamoyl%2529oxy%2529methyl%2529cyclohexyl%2529methoxy%2529acetate%2B%2528Ralinepag%2529%253A%2BAn%2BOrally%2BActive%2BProstacyclin%2BReceptor%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BPulmonary%2BArterial%2BHypertension%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D927%26publicationDate%3DFebruary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00871"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1677</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00871" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Thuy-Anh&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;Kramer&quot;},{&quot;first_name&quot;:&quot;Young-Jun&quot;,&quot;last_name&quot;:&quot;Shin&quot;},{&quot;first_name&quot;:&quot;Pureza&quot;,&quot;last_name&quot;:&quot;Vallar&quot;},{&quot;first_name&quot;:&quot;P.&quot;,&quot;last_name&quot;:&quot;Douglas Boatman&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Carleton&quot;,&quot;last_name&quot;:&quot;R. Sage&quot;},{&quot;first_name&quot;:&quot;Tawfik&quot;,&quot;last_name&quot;:&quot;Gharbaoui&quot;},{&quot;first_name&quot;:&quot;Ashwin&quot;,&quot;last_name&quot;:&quot;Krishnan&quot;},{&quot;first_name&quot;:&quot;Biman&quot;,&quot;last_name&quot;:&quot;Pal&quot;},{&quot;first_name&quot;:&quot;Sagar&quot;,&quot;last_name&quot;:&quot;R. Shakya&quot;},{&quot;first_name&quot;:&quot;Antonio&quot;,&quot;last_name&quot;:&quot;Garrido Montalban&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;W. Adams&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Ramirez&quot;},{&quot;first_name&quot;:&quot;Dominic&quot;,&quot;last_name&quot;:&quot;P. Behan&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Shifrina&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Blackburn&quot;},{&quot;first_name&quot;:&quot;Tina&quot;,&quot;last_name&quot;:&quot;Leakakos&quot;},{&quot;first_name&quot;:&quot;Yunqing&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Morgan&quot;},{&quot;first_name&quot;:&quot;Abu&quot;,&quot;last_name&quot;:&quot;Sadeque&quot;},{&quot;first_name&quot;:&quot;Weichao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;J. Unett&quot;},{&quot;first_name&quot;:&quot;Ibragim&quot;,&quot;last_name&quot;:&quot;Gaidarov&quot;},{&quot;first_name&quot;:&quot;Xiaohua&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Hsin-Hui&quot;,&quot;last_name&quot;:&quot;Shu&quot;},{&quot;first_name&quot;:&quot;Shiu-Feng&quot;,&quot;last_name&quot;:&quot;Tung&quot;},{&quot;first_name&quot;:&quot;Graeme&quot;,&quot;last_name&quot;:&quot;Semple&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;913-927&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00871&quot;},&quot;abstract&quot;:&quot;The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described. Detailed profiling of a number of analogues resulted in the identification of 5c (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor. In our hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clinical compound NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays. 5c had an excellent PK profile across species. Enterohepatic recirculation most probably contributes to a concentration–time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio. Following the identification of an acceptable solid form, 5c was selected for further development for &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00871&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00871" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00871&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00871" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00871&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00871" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00871&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00871&amp;href=/doi/10.1021/acs.jmedchem.6b00871" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00871" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00871" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (725 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00871%26sid%3Dliteratum%253Aachs%26pmid%3D28072531%26genre%3Darticle%26aulast%3DTran%26date%3D2017%26atitle%3DDiscovery%2Bof%2B2-%2528%2528%25281r%252C4r%2529-4-%2528%2528%25284-Chlorophenyl%2529%2528phenyl%2529carbamoyl%2529oxy%2529methyl%2529cyclohexyl%2529methoxy%2529acetate%2B%2528Ralinepag%2529%253A%2BAn%2BOrally%2BActive%2BProstacyclin%2BReceptor%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BPulmonary%2BArterial%2BHypertension%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D3%26spage%3D913%26epage%3D927%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/jmcmar.2017.60.issue-3/20170209/jmcmar.2017.60.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described. Detailed profiling of a number of analogues resulted in the identification of <b>5c</b> (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor. In our hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clinical compound NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays. <b>5c</b> had an excellent PK profile across species. Enterohepatic recirculation most probably contributes to a concentration–time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio. Following the identification of an acceptable solid form, <b>5c</b> was selected for further development for the treatment of PAH.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pulmonary arterial hypertension (PAH) is a rare but life-threatening disease. The pathogenesis, which is thought to result in part from an imbalance in the production of two cyclooxygenase metabolites of arachidonic acid, prostacyclin (PGI2) and thromboxane A2,<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> includes pulmonary vasoconstriction, endothelial and smooth muscle cell proliferation, tissue remodeling, and platelet mediated thrombosis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The protective effects of PGI2 arise via activation of the prostacyclin receptor (IP) which leads to stimulation of adenylate cyclase, with a resulting increase in intracellular cAMP levels, in platelets, smooth muscle cells, and immune cells. Therapeutic substitution of PGI2 or its analogues in PAH patients can reduce pulmonary artery pressure and slow disease progression.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This class of compounds generally has short half-lives in vivo due to chemical and metabolic instability and has to be dosed by repeated inhalation or continuous intravenous infusion. As a result, many of these drugs have limited and sometimes problematic clinical application. Other drug classes have also been investigated for this indication, and several orally available endothelin antagonists (that act by blocking the vasoconstrictive effects of endothelin peptides) and PDE5 inhibitors (that act by blocking the degradation of cGMP which is vasodilatory) have been approved creating a multibillion dollar market and an improvement in patient care in this disease area.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> To improve upon the currently approved prostacyclin based drugs and to be more competitive with the other classes in terms of compliance, stable, orally bioavailable PGI2 analogs and non-prostanoid IP receptor agonists have been investigated.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> One such compound, NS-304 or selexipag, <b>1</b> which is a prodrug of the active species MRE269 (<b>2</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> was recently approved for the treatment of PAH.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selexipag and its active metabolite.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The larger prostanoid ligand family evokes diverse biological actions in many tissues and cell types by binding to multiple specific cell surface G-protein-coupled receptors including prostaglandin D<sub>2</sub> receptors (DP1, DP2), prostaglandin E<sub>2</sub> receptors (EP1, EP2, EP3, EP4), prostaglandin F<sub>2a</sub> receptor (FP), and the thromboxane receptor (TP) in addition to IP. Thus, we sought to design new prostacyclin receptor agonists with significantly improved pharmacokinetic profiles that, like selexipag, might be dosed orally but that would not require metabolic activation while staying mindful of the requirement for good receptor selectivity to avoid other prostaglandin mediated activities. Although the majority of clinical side effects of current prostacyclin agonists are thought to be on target, activation of other prostaglandin receptors, such as EP3 in the gut for example, may contribute to some of the GI symptoms observed with previous agents.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Designing and Synthesis of a New Series of IP Agonists</h3><div class="NLM_p">For our earlier approaches to new IP receptor agonists, we surveyed multiple series of compounds designed from an understanding of the structural requirements for activity based on previously known non-prostanoid IP receptor agonists.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Compounds of this type were shown to be potent agonists of the IP receptor with good selectivity over most prostanoid receptor family members but only very modest selectivity over the DP1 receptor. <b>3</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) was optimal in this series but had an IP to DP1 selectivity ratio of just 8-fold. Analogues from this series did demonstrate in vivo activity after sc dosing in the widely used rat monocrotaline model of PAH.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, this early design process failed to provide compounds with significant oral activity in the same model. As a result, our redesign of these initial prostacyclin agonist series focused on three key objectives. The first was to improve selectivity over DP1. Second, we aimed to reduce aromatic ring count and lipophilicity in an effort to improve the in vivo, and eventually the clinical, profile. It has been suggested that either an increase in the sp<sup>3</sup> character<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> or the reduction in the number of aromatic rings in candidate drugs may correlate with improved clinical success.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Finally, we were interested in significantly reducing the cycle times for synthesis and testing by trying to target compounds with a shorter synthetic route compared to the 10–14 step syntheses required to prepare our first series. We achieved the second of these objectives by deleting the fused aromatic ring in our first series (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>; <i>F</i>(sp<sup>3</sup>) was increased by 2-fold, albeit without any significant change in clogP). This approach had the added advantage of removing a chiral center which helped to simplify the synthesis, although two alternative relative stereochemical arrangements are possible. In addition, as this type of scaffold was new in the prostaglandin space, it also opened up a number of additional possibilities for the linker group that serves to orientate the two required aromatic groups, giving us a further opportunity to reduce synthetic complexity. After briefly investigating a number of such linker–aromatic combinations, including using both of the pyridazinone building blocks as well as some related heterocycles we explored previously, we quickly settled on the carbamate series <b>5</b>, which was relatively simple to prepare in only a few steps.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Simplification approach to redesign of prostacyclin agonist series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For our initial investigation, we prepared both the <i>cis-</i> and <i>trans-</i>analogues for a number of biaryl carbamates by using either the <i>cis-</i> or <i>trans-</i>cyclohexanedimethanol building block (<b>6</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) and reacting it with the appropriate isocyanate (e.g., R<sub>1</sub> = H) to provide <b>7</b>. The alcohol was then elongated using a rhodium acetate catalyzed insertion reaction with <i>tert</i>-butyl diazoacetate to provide the <i>tert</i>-butyl ester <b>8</b> in good yield. The target compounds were then prepared in parallel format by direct Ullman-like arylation of the carbamate to give <b>9</b> followed by simple acid catalyzed deprotection of the ester group to provide the desired compounds <b>5</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Library Route for the Preparation of the Cyclohexyl Scaffold/Carbamate Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) R<sup>1</sup>PhNCO, pyridine; (ii) <i>tert</i>-butyl diazoacetate, (Rh(OAc)<sub>2</sub>)<sub>2</sub>; (iii) R<sup>2</sup>I, CuI, K<sub>3</sub>PO<sub>4</sub>, microwave; (iv) HCl, dioxane.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> In Vitro SAR of New Series</h3><div class="NLM_p">The new compounds were tested for functional agonist activity in a standard (Cisbio) cAMP assay using recombinant IP or DP1 receptors stably expressed in CHO-K1 cells. Clonal cell lines were derived following standard protocols, but receptor expression levels were kept to a minimum to preclude receptor reserve effects. To streamline our screening process, we focused on the DP1 receptor as the most likely off-target issue based on the experience with our earlier series as discussed above and that the new compounds had been designed using modifications to that series. In addition, the first compound in the series <b>5a</b> showed no activity at prostaglandin receptors other than DP1 based on a panel assays in melanophores. More extensive profiling with other family receptors was therefore performed only on potential preclinical candidate compounds. This approach was later shown to be flawed when we noted some previously unseen off-target activity with compounds that were more potent than <b>5a</b> on the IP receptor. Our new compounds were compared to <b>2</b> (the active metabolite of the approved compound <b>1</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a>) for receptor potency and intrinsic activity at the IP receptor, as we felt this to be the most appropriate comparator compound for our program, as at the time <b>1</b> was the only orally acting non-prostanoid IP agonist drug in development. In all cases (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) the <i>trans</i>-relative stereochemical arrangement provided compounds with significantly greater potency in the human IP receptor cAMP assay than their <i>cis</i>-counterparts (<b>5a</b>–<b>h</b>), with the biggest difference being observed between the 4-methoxy analogues <b>5e</b> and <b>5f</b>. From this point onward, only the <i>trans</i>-isomers were prepared as we attempted to further optimize the series.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Screening Data for Selected Analogues<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0004.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">rel conf</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> hIP,<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a>nM (% IA)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> rIP,<a class="ref internalNav" href="#t1fn4" aria-label="c">c</a>nM (% IA)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> hDP1,<a class="ref internalNav" href="#t1fn5" aria-label="d">d</a>nM (% IA<a class="ref internalNav" href="#t1fn6" aria-label="e">e</a>)</th><th class="colsep0 rowsep0" align="center">human platelet, IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn7" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">human and rat MS, <i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t1fn8" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6 (98)</td><td class="colsep0 rowsep0" align="left">200 (100)</td><td class="colsep0 rowsep0" align="left">100 (48)</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">21 (77)</td><td class="colsep0 rowsep0" align="left">365 (89)</td><td class="colsep0 rowsep0" align="left">355 (59)</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left"><i>cis</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">54 (81)</td><td class="colsep0 rowsep0" align="left">472 (94)</td><td class="colsep0 rowsep0" align="left">1710 (68)</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">8.5 (85)</td><td class="colsep0 rowsep0" align="left">530 (88)</td><td class="colsep0 rowsep0" align="left">850 (52)</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left"><i>cis</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">46 (80)</td><td class="colsep0 rowsep0" align="left">560 (88)</td><td class="colsep0 rowsep0" align="left">980 (60)</td><td class="colsep0 rowsep0" align="left">166</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">3.3 (83)</td><td class="colsep0 rowsep0" align="left">165 (91)</td><td class="colsep0 rowsep0" align="left">240 (74)</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left"><i>cis</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">1630 (16)</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">8.7 (85)</td><td class="colsep0 rowsep0" align="left">284 (83)</td><td class="colsep0 rowsep0" align="left">2760 (61)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left"><i>cis</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">62 (79)</td><td class="colsep0 rowsep0" align="left">561 (88)</td><td class="colsep0 rowsep0" align="left">3870 (61)</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5i</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">19 (80)</td><td class="colsep0 rowsep0" align="left">272 (88)</td><td class="colsep0 rowsep0" align="left">5070 (30)</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="left">12 (92)</td><td class="colsep0 rowsep0" align="left">470 (94)</td><td class="colsep0 rowsep0" align="left">1720 (68)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">h, >60; r, 53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">3.9 (81)</td><td class="colsep0 rowsep0" align="left">174 (99)</td><td class="colsep0 rowsep0" align="left">320 (53)</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">6.6 (89)</td><td class="colsep0 rowsep0" align="left">535 (91)</td><td class="colsep0 rowsep0" align="left">620 (55)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-Cl, 3-F</td><td class="colsep0 rowsep0" align="left">3.4 (85)</td><td class="colsep0 rowsep0" align="left">400 (92)</td><td class="colsep0 rowsep0" align="left">2050 (38)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-Cl, 4-F</td><td class="colsep0 rowsep0" align="left">38 (79)</td><td class="colsep0 rowsep0" align="left">1330 (102)</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">142</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3,4-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">10 (88)</td><td class="colsep0 rowsep0" align="left">640 (95)</td><td class="colsep0 rowsep0" align="left">5000 (45)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">5.2 (70)</td><td class="colsep0 rowsep0" align="left">1570 (60)</td><td class="colsep0 rowsep0" align="left">1030 (65)</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5q</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">18.5 (70)</td><td class="colsep0 rowsep0" align="left">3190 (44)</td><td class="colsep0 rowsep0" align="left">1140 (35)</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5r</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">41 (65)</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">860 (45)</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5s</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">7.8 (76)</td><td class="colsep0 rowsep0" align="left">1630 (54)</td><td class="colsep0 rowsep0" align="left">808 (57)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5t</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">4-Cl, 3-F</td><td class="colsep0 rowsep0" align="left">23 (75)</td><td class="colsep0 rowsep0" align="left">2720 (56)</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">h, >60; r, >60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">22 (60)</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">154 (80)</td><td class="colsep0 rowsep0" align="left">288</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iloprost</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.4 (101)</td><td class="colsep0 rowsep0" align="left">0.69 (99)</td><td class="colsep0 rowsep0" align="left">147 (42)</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">nd = not determined. rel conf = relative stereochemical configuration of the 1,4-substituents around the cyclohexyl ring core.</p></div><div class="footnote" id="t1fn3"><sup>b</sup><p class="last">EC<sub>50</sub> in the HTRF (cAMP) human or rat IP receptor assay. Data are the mean of at least three determinations with log(SD) < 0.33.</p></div><div class="footnote" id="t1fn4"><sup>c</sup><p class="last">Intrinsic activity (efficacy) relative to 1 μM iloprost as the positive control.</p></div><div class="footnote" id="t1fn5"><sup>d</sup><p class="last">EC<sub>50</sub> in the HTRF (cAMP) human DP1 receptor assay. Data are the mean of at least three determinations with log(SD) < 0.4.</p></div><div class="footnote" id="t1fn6"><sup>e</sup><p class="last">Intrinsic activity (efficacy) relative to 1 μM PGD<sub>2</sub> as the positive control.</p></div><div class="footnote" id="t1fn7"><sup>f</sup><p class="last">Inhibition of ADP-induced human platelet aggregation. Data are the mean of at least two determinations. All compounds with a measurable IC<sub>50</sub> were able to fully inhibit the platelet aggregation induced by ADP.</p></div><div class="footnote" id="t1fn8"><sup>g</sup><p class="last">Half-life after incubation at 37 °C in human and rat microsome preparations.</p></div></div></div><div class="NLM_p last">The SAR of the substituents on the aromatic ring groups was broadly similar to that observed in our earlier series.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Substitution of one of the aromatic rings with a 3- or 4-halo substituent provided compounds with single digit nanomolar potency and high intrinsic activity (agonist efficacy relative to 1 μM iloprost as a positive control) in the IP cAMP assay and in some cases >100-fold selectivity over DP1 in the same assay platform. A 3- or 4-methoxy group (<b>5e</b> and <b>5j</b>) on one of the phenyl rings again provided analogues with single or double digit nanomolar potency and reasonable selectivity and was the most polar substituent that was tolerated. The in vitro potency and intrinsic activity of these monosubstituted analogues were comparable to data for <b>2</b> in our hands (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) with a marginal improvement in functional selectivity with respect to DP1. An additional halogen substituent on either the same ring or the second aromatic ring did not improve receptor potency significantly and for a number of examples (<b>5q</b>–<b>u</b>) appeared to decrease efficacy. We were speculating at this stage that greater receptor efficacy may eventually offer an advantage for our series in further pharmacological measurements or in clinical testing, and so only compounds where there was a statistically significant improvement in intrinsic activity over <b>2</b> were considered for further studies.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Early Compound Profiling</h3><div class="NLM_p">In addition to its function as a direct vasodilator, prostacyclin can also inhibit ADP-induced platelet aggregation. Such aggregated and activated platelets produce vasoactive substances such as thromboxane and serotonin that may cause harmful vasoconstriction and vascular remodeling.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> We thus measured the activity of our compounds to confirm the data from the recombinant receptor assay by testing in a primary human platelet aggregation assay as a potentially disease-relevant, physiological readout. This secondary assay was carried out as previously described,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> with aggregation induced by 2.5 μM ADP in the presence or absence of IP receptor agonists. The activity of all compounds in this assay was broadly reflective of their agonist effect in the cloned IP receptor assay with an approximate 2- to 10-fold difference in the observed potency. Again the potency of our compounds compared favorably to the inhibition IC<sub>50</sub> observed for <b>2</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), although all compounds, regardless of efficacy in the cloned IP receptor assay, were able to achieve 100% inhibition of the aggregation response if tested at a high enough concentration.</div><div class="NLM_p">We did note, however, that all of the compounds in our series had a rather poor effect when tested against the rat IP receptor, with EC<sub>50</sub> values typically 10- to 30-fold weaker than for the human receptor, and we thus had some concerns about being able to demonstrate in vivo pharmacological activity in the rat. Despite this, several compounds with good human receptor potency and selectivity, which in general all had excellent stability in microsomes from both human and rat (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), were surveyed for their PK properties in rat (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PK Parameters from Rat PK Screening of Selected IP Agonists<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose iv/po (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>obs</sub> (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–inf</sub>(hr·μg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">2.71</td><td class="colsep0 rowsep0" align="char" char=".">14.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">2.74</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">2.1/10.5</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">1.43</td><td class="colsep0 rowsep0" align="char" char=".">0.833</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last"><i>C</i><sub>max</sub> = maximal plasma concentration reached after oral administration. <i>T</i><sub>max</sub> = time to reach the maximal plasma concentration after oral administration. <i>T</i><sub>1/2</sub> = terminal half-life after iv administration at 2 mg/kg. <i>F</i> = % oral bioavailability. AUC<sub>0–inf</sub> = exposure (area under the curve) after oral administration. Cl<sub>obs</sub> = total clearance rate. <i>V</i><sub>ss</sub> = volume of distribution.</p></div></div></div><div class="NLM_p last">On the basis of the combination of the in vitro activity/selectivity and the PK data obtained from this selection of compounds in particular the high <i>C</i><sub>max</sub> values, <b>5c</b>, <b>5g</b>, and <b>5m</b> were identified as three potential candidates for testing in our rat in vivo monocrotaline (MCT) model. The two methoxy substituted compounds (<b>5e</b> and <b>5j</b>) were discarded when we observed high clearance and a moderate <i>C</i><sub>max</sub> after oral administration in vivo. As the in vivo assay required chronic administration of compounds and was time and resource intensive, we were limited to the selection of two compounds to progress at this stage. Of the three compounds of interest remaining, <b>5c</b> had the highest total exposure (AUC), as well as longest half-life in the rat, which we felt provided the best opportunity to observe in vivo pharmacological activity. For the second selection we preferred <b>5g</b> over <b>5m</b>. Although both were more potent than <b>5c</b> at the rat receptor, which we thought may also be important, and each had excellent in vitro selectivity for the human IP receptor over the DP1 receptor, <b>5g</b> had significantly higher total exposure (AUC) in the rat PK study.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Scale-Up and in Vivo Testing of Selected Compounds</h3><div class="NLM_p">For testing in the 21-day in vivo MCT model, the two compounds selected needed to be resynthesized on a multigram scale. Having already narrowed down the range of biaryl carbamate groups of interest to just two and in view of the unpredictable yields from the copper catalyzed arylation of <b>8</b>, we elected to start from the requisite biarylamine <b>10</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, method 1). For <b>5c</b>, the starting material 4-chloro-<i>N</i>-phenylaniline was commercially available and <b>11</b> (R<sup>1</sup> = H, R<sup>2</sup> = 3-F), the starting material for the preparation of <b>5g</b> which was not then readily available, was prepared by Buchwald coupling of 3-fluoroaniline (<b>10</b>, R<sup>2</sup> = 3-F) with bromobenzene. Treatment of the biarylamines with triphosgene at 0 °C in pyridine provided the intermediates <b>12</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) and <b>12</b> (R<sup>1</sup> = H, R<sup>2</sup> = 3-F) that could be isolated. For the 3-fluoro analogue, the yield in the next reaction was enhanced by activation of this intermediate with DMAP, but in the case of <b>12</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) the chlorocarbamate was reacted directly with <i>trans</i>-1,4-cyclohexanedimethanol to provide <b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl). The sequence was completed with the carbene insertion reaction using <i>tert</i>-butyl diazoacetate followed by ester hydrolysis with HCl/dioxane.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Larger Scale Syntheses of the Cyclohexyl Scaffold/Carbamate Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method 1: [R<sup>1</sup> = 4-Cl or 3-F, R<sup>2</sup> = H] (i) [R<sup>2</sup> = 3-F] PhBr, KO<i><sup>t</sup></i>Bu, Pd(dppf)Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, toluene; (ii) triphosgene, pyridine, 0 °C; (iii) [X = Cl] (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol, pyridine, heat; (iv) <i>tert</i>-butyl diazoacetate, (Rh(OAc)<sub>2</sub>)<sub>2</sub> (v) HCl, dioxane. Method 2: [R<sup>1</sup> = 4-Cl, R<sup>2</sup> = H] (ii) carbonyldiimidazole, acetonitrile, K<sub>3</sub>PO<sub>4</sub>; (iii) [X = 1-imidazole] (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (4 equiv), acetonitrile, 65 °C (68–78% two steps); (iv) ethyl bromoacetate, tetrabutylammonium bromide, 50% NaOH, toluene; (v) (a) heat; (b) HCl (62–67% two steps).</p></p></figure><div class="NLM_p">When dosed in the MCT model in a preventative mode, both compounds demonstrated a dose-dependent inhibition of the increase in the ratio of right ventricular weight to the combined weight of left ventricle and septum (RV/(LV +S)) induced by administration of monocrotaline (data for <b>5c</b> are shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>; data for <b>5g</b> are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">Supporting Information</a>), indicative of an inhibitory effect on the development of right ventricular hypertrophy. At the highest dose of 30 mg/kg twice daily for 21 consecutive days after the initiation of the insult with monocrotaline, RV/(LV + S) values were similar to those in sham controls. Supporting the observed effect on hypertrophy, <b>5c</b> was able to significantly reduce the MCT-induced increase in pulmonary arterial pressure in a subset of the test group (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) and pulmonary vessel wall thickness in 5 animals (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">Supporting Information</a>) at the highest dose of 30 mg/kg.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of <b>5c</b> in the MCT model after oral administration. MCT = monocrotaline; Veh = vehicle; RV/(LV + S) = ratio of right ventricle weight to weight of left ventricle plus septum, an index of right ventricular hypertrophy (<i>n</i> = 8 for sham, <i>n</i> = 8 for MCT + veh group and <i>n</i> = 10 for <b>5c</b> treatment groups); mPAP = mean pulmonary arterial pressure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As might be expected from such highly lipophilic carboxylic acid compounds (clogP for <b>5c</b> = 5.6; clogP for <b>5g</b> = 5.0), plasma protein binding was very high (∼99%, i.e., 1% free fraction) for each across all species. The unbound <i>C</i><sub>max</sub> plasma concentrations for <b>5c</b> and <b>5g</b> after a single oral dose at 30 mg/kg were estimated to be 300 nM (based on a 1% free fraction of the measured <i>C</i><sub>max</sub> of a 30 mg/kg dose in a separate experiment designed to measure dose proportionality). Although agonists of some GPCRs with very efficient coupling can achieve full activation of the receptor at very low receptor occupancy, it is worth noting in this case that the unbound plasma concentrations in vivo were in the same range as the in vitro EC<sub>50</sub> values for the two compounds at the recombinant rat IP receptor cAMP assay. In addition, the unbound <i>C</i><sub>max</sub> for <b>5c</b> following the ineffective 10 mg/kg dose was around 100 nM (as calculated from the PK experiment) which is 5-fold lower than the EC<sub>50</sub> at the rat IP receptor. This provided a possible explanation for the lack of effect at this dose and allowed for a hypothesis as to the required efficacious human exposure requirements. It remains unclear however that the same correlation can be made in human, as the cAMP assay may not be the most relevant readout.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Further Profiling</h3><div class="NLM_p">Encouraged by these data, we carried out more extensive profiling of <b>5c</b> and <b>5g</b>. In radioligand binding assays of affinity for the IP receptor in multiple species, there was little to choose between the two compounds (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). In addition, <b>5c</b> and <b>5g</b> showed good binding selectivity over almost all the related prostaglandin receptor subtypes tested, with the exception of EP3, and in a wider screen no additional off-target liabilities were observed.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Again, we noted clear species differences for the IP receptor affinities and the difference between the human and rat receptor was similar to that observed in the IP cAMP functional assays. In HTRF cAMP functional assays for other family members, no significant agonist activity was observed at the other receptors tested (EP2, EP4), suggesting that any functional activity arising from the modest binding affinity to these prostanoid receptors would most likely be in the antagonist direction. In contrast to our earlier series, the prostaglandin receptor for which <b>5c</b> and <b>5g</b> had the most significant receptor binding affinity was human EP3 (the EP3v6 form of the receptor was used for the study) and an EP3/IP binding selectivity ratio of 30- to 50-fold was observed. This was a surprise to us, as no previous series of IP agonists we had tested (including <b>2</b>) had any affinity for this receptor. Unlike IP, EP2, and EP4, EP3 is a G<sub>i</sub> coupled receptor, and as a result functional selectivity is not directly comparable in a cAMP assay as forskolin activation is required making a functional selectivity comparison difficult to quantify. In our melanophore platform, however,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> both compounds behaved as EP3 agonists with potencies similar to their binding affinities (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">Supporting Information data</a>). Again, a true functional selectivity is difficult to deduce, but the data were similar to the agonist effect seen for iloprost in the EP3 melanophore assay. We were satisfied though, based on the binding (K<sub>i</sub>) data, that the receptor selectivity for these two compounds was adequate for us to proceed but with a requirement to monitor potential EP3 mediated effects.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Radioligand Binding Assay Profiling of Potential Lead Compounds on Cloned Human Receptors and Prostacyclin Receptors from Other Preclinical Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center"><i>K</i><sub>i</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">binding assay (ligand)</th><th class="colsep0 rowsep0" align="center"><b>5c</b></th><th class="colsep0 rowsep0" align="center"><b>5g</b></th><th class="colsep0 rowsep0" align="center">iloprost</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IP ([<sup>3</sup>H]-iloprost)</td><td class="colsep0 rowsep0" align="left">0.003 (<i>n</i> = 6; log SD = 0.34)</td><td class="colsep0 rowsep0" align="left">0.007 (<i>n</i> = 5; log SD = 0.28)</td><td class="colsep0 rowsep0" align="left">0.0032 (<i>n</i> = 25; log SD = 0.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DP<sub>1</sub> ([<sup>3</sup>H]-PGD2)</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">1.85</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EP<sub>1</sub> ([<sup>3</sup>H]-PGE2)</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EP<sub>2</sub> ([<sup>3</sup>H]-PGE2)</td><td class="colsep0 rowsep0" align="left">0.610</td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EP<sub>3v6</sub> ([<sup>3</sup>H]-PGE2)</td><td class="colsep0 rowsep0" align="left">0.143 (<i>n</i> = 3; log SD = 0.07)</td><td class="colsep0 rowsep0" align="left">0.210 (<i>n</i> = 3; log SD = 0.3)</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EP<sub>4</sub> ([<sup>3</sup>H]-PGE2)</td><td class="colsep0 rowsep0" align="left">0.678</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat IP ([<sup>3</sup>H]-iloprost)</td><td class="colsep0 rowsep0" align="left">0.076 (<i>n</i> = 3; log SD = 0.21)</td><td class="colsep0 rowsep0" align="left">0.051 (<i>n</i> = 3; log SD = 0.2)</td><td class="colsep0 rowsep0" align="left">0.001 (<i>n</i> = 3; log SD = 0.09)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog IP ([<sup>3</sup>H]-iloprost)</td><td class="colsep0 rowsep0" align="left">0.256 (<i>n</i> = 5; log SD = 0.16)</td><td class="colsep0 rowsep0" align="left">0.183 (<i>n</i> = 3; log SD = 0.23)</td><td class="colsep0 rowsep0" align="left">0.0017 (<i>n</i> = 8; log SD = 0.13)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey IP ([<sup>3</sup>H]-iloprost)</td><td class="colsep0 rowsep0" align="left">0.0012 (<i>n</i> = 6; log SD = 0.16)</td><td class="colsep0 rowsep0" align="left">0.0026 (<i>n</i> = 3; log SD = 0.07)</td><td class="colsep0 rowsep0" align="left">0.0016 (<i>n</i> = 11; log SD = 0.13)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Data are the mean of two determinations unless otherwise stated.</p></div></div></div><div class="NLM_p">Since GPCR functional assays performed in cells expressing high levels of recombinant receptors can often be influenced by receptor reserve effects, which may exaggerate potency and efficacy, further studies at the human IP receptor were performed to carefully characterize the in vitro potency and efficacy of <b>5c</b> and <b>5g</b>. Thus, a series of assays were performed in which receptor expression levels were systematically reduced. In addition, cAMP assays were performed in primary human pulmonary arterial smooth muscle cells. When we reached a level of no receptor reserve in the recombinant assay, the potency and efficacy data were essentially identical in each system (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">Supporting Information</a>). In both of these assay systems, as well as the screening assay, <b>5c</b> showed significantly greater potency and efficacy than <b>2</b>. Further assays in pulmonary arterial smooth muscle cells (PASMC) from PAH patients have recently been reported that also showed a greater efficacy for <b>5c</b> in increasing cAMP levels compared to <b>2</b> (an effect that was blocked for both compounds by the IP antagonist RO-1138452), although there was no difference in EC<sub>50</sub>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">Finally, as part of our in vitro evaluations, neither <b>5c</b> nor <b>5g</b> showed any measurable inhibition of the most highly expressed cytochrome P450 enzymes (IC<sub>50</sub> > 50 μM for CYPs 1A2, 2D6, 3A4 2C8, 2C9, and 2C19) and no inhibition of hERG channel functional activity was observed in a patch clamp assay (IC<sub>50</sub> > 30 μM).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Selection of a Development Candidate</h3><div class="NLM_p">The first meaningful differentiation between the two compounds was observed during our early solid state characterization. Surprisingly, although the structures of the two compounds were very similar, both the free acid (mp ∼128 °C) and the sodium salt (mp ∼243 °C) of <b>5c</b> were crystalline and nonhygroscopic solids, whereas the free acid of <b>5g</b> was an oil and the sodium salt was a low melting monohydrate (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">Supporting Information</a>). It was on the basis of these data that the 4-chloro analogue <b>5c</b> was selected for further investigation as it had two potential solid state forms that met our in-house solid state screening developability criteria. <b>5g</b> on the other hand had only a single acceptable solid form which, being a hydrate, may have had a higher likelihood of running into issues in development. In addition, when we investigated further scale up synthesis methods, all key synthetic intermediates for <b>5c</b> could be isolated as solids. This was not the case for <b>5g</b> which might also have presented significant development challenges.</div><div class="NLM_p"><b>5c</b> was subsequently prepared in kilogram amounts using some modifications to the first scale-up route, primarily directed toward improving early process safety by the replacement of phosgene and the carbene insertion reactions with more benign alternatives (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, method 2) and toward shortening the overall procedure by telescoping some steps. Hence, <b>11</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) was treated with 1,1′-carbonyldiimidazole (CDI) in acetonitrile in the presence of potassium phosphate. After this first reaction was complete, the intermediate <b>12</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) was not isolated but rather excess 1,4-<i>trans</i>-cyclohexane dimethanol was added to the reaction mixture to provide <b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) which was isolated by removal of acetonitrile and precipitation from water. <b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) was alkylated with <i>tert</i>-butyl bromoacetate utilizing 50% aqueous sodium hydroxide and tetrabutylammonium bromide in toluene. On reaction completion, the intermediate <i>tert</i>-butyl ester was simply heated to hydrolyze the ester. The resultant acid was isolated as the sodium salt which crystallized from aqueous acetone. The sodium salt could then be acidified with hydrochloric acid and the free acid of <b>5c</b> isolated by filtration with purity in excess of 99%.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">With now a significant amount of material in hand we were able to collect additional data to confirm the nomination of <b>5c</b> for further development. In PK studies across a number of preclinical species <b>5c</b> exhibited dose-dependent exposure with good bioavailability after oral administration in all species tested (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">Supporting Information</a>). Particularly noteworthy was the concentration–time profile and long elimination half-life in the monkey. <b>5c</b> appeared to have a very low peak-to-trough ratio in the range of 3–5 following oral administration, suggesting that this compound might have an advantageous profile in the clinic. As the majority of the side effects observed with prostacyclin therapies, such as flushing, systemic hypotension, and jaw pain, are believed to be largely on target, they may be greatly ameliorated by such minimal fluctuations in plasma exposure if these can be confirmed in human studies. Such tight control of plasma levels may therefore be expected to provide improved tolerability compared to existing prostacyclin treatments. In addition, the long half-life in preclinical species also strongly suggested the possibility for once daily oral formulation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters of <b>5c</b> after Administration to Male CD-1 Mice, Sprague-Dawley Rats, Beagle Dogs, and Cynomolgus Monkeys<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">(1) After Intravenous Administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">iv dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">Cl<sub>obs</sub> (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–inf</sub> (h·μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">5.59</td><td class="colsep0 rowsep0" align="left">0.689</td><td class="colsep0 rowsep0" align="left">3.66</td><td class="colsep0 rowsep0" align="left">2.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">6.72 ± 0.98</td><td class="colsep0 rowsep0" align="left">0.427 ± 0.163</td><td class="colsep0 rowsep0" align="left">2.74 ± 1.11</td><td class="colsep0 rowsep0" align="left">5.09 ± 1.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">3.54 ± 0.42</td><td class="colsep0 rowsep0" align="left">0.202 ± 0.057</td><td class="colsep0 rowsep0" align="left">0.308 ± 0.050</td><td class="colsep0 rowsep0" align="left">1.05 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">24.2 ± 2.1</td><td class="colsep0 rowsep0" align="left">0.881 ± 0.579</td><td class="colsep0 rowsep0" align="left">10.1 ± 0.6</td><td class="colsep0 rowsep0" align="left">0.145 ± 0.095</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="7" align="center">(2) After Oral Administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">po dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–inf</sub> (h·μg/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">9.49</td><td class="colsep0 rowsep0" align="left">8.08</td><td class="colsep0 rowsep0" align="left">4.94</td><td class="colsep0 rowsep0" align="left">0.250</td><td class="colsep0 rowsep0" align="left">11.5</td><td class="colsep0 rowsep0" align="left">83.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">10.0</td><td class="colsep0 rowsep0" align="left">5.45 ± 1.52</td><td class="colsep0 rowsep0" align="left">3.70 ± 1.34</td><td class="colsep0 rowsep0" align="left">1.50 ± 0.87</td><td class="colsep0 rowsep0" align="left">14.6 ± 3.41</td><td class="colsep0 rowsep0" align="left">57.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">9.79 ± 0.94</td><td class="colsep0 rowsep0" align="left">0.327 ± 0.016</td><td class="colsep0 rowsep0" align="left">0.417 ± 0.144</td><td class="colsep0 rowsep0" align="left">0.719 ± 0.290</td><td class="colsep0 rowsep0" align="left">68.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5.53 ± 1.48</td><td class="colsep0 rowsep0" align="left">3.44 ± 0.90</td><td class="colsep0 rowsep0" align="left">0.833 ± 0.289</td><td class="colsep0 rowsep0" align="left">9.75 ± 5.27</td><td class="colsep0 rowsep0" align="left">92.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">17.5 ± 3.4</td><td class="colsep0 rowsep0" align="left">0.0121 ± 0.0036</td><td class="colsep0 rowsep0" align="left">2.67 ± 2.89</td><td class="colsep0 rowsep0" align="left">0.161 ± 0.116</td><td class="colsep0 rowsep0" align="left">98.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">38.7 ± 21.3</td><td class="colsep0 rowsep0" align="left">0.0928 ± 0.0297</td><td class="colsep0 rowsep0" align="left">4.17 ± 3.18</td><td class="colsep0 rowsep0" align="left">2.90 ± 1.35</td><td class="colsep0 rowsep0" align="left">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last"><i>C</i><sub>max</sub> = maximal plasma concentration reached after oral administration. <i>T</i><sub>max</sub> = time to reach the maximal plasma concentration after oral administration. <i>T</i><sub>1/2</sub> = terminal half-life after iv administration at 2 mg/kg. <i>F</i> = % oral bioavailability. AUC<sub>0–inf</sub> = exposure (area under the curve). Cl<sub>obs</sub> = total clearance rate. <i>V</i><sub>ss</sub> = volume of distribution.</p></div></div></div><div class="NLM_p">One explanation for the prolonged exposure was the possibility of enterohepatic recirculation. This suggestion was inferred from concentration–time profiles in PK studies across species in which a second, delayed absorption phase was routinely observed. A more definitive study was therefore conducted in bile-duct cannulated (BDC) rats. After an intravenous administration of <b>5c</b> to either normal or BDC rats, the second absorption phase was eliminated in the BDC rats with an accompanying 3-fold reduction in the apparent plasma half-life, supporting the suggestion of recycling of <b>5c</b> back to the plasma via bile excretion into the gut in normal rats. Concentrations of <b>5c</b> were negligible in bile and urine compared to plasma indicating that the major path of elimination was hepatic metabolism and that a conjugated species may be involved.</div><div class="NLM_p">A taurine-conjugated metabolite was subsequently identified in bile (M1, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), which was also observed in circulating plasma, although at much lower concentrations (∼5%) compared to parent. Further, two oxidized products, one of which was also a taurine-conjugate, were identified (M2 and M3) in plasma. Both conjugated metabolites of <b>5c</b> had weak activity at the IP receptor (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), whereas the low level metabolite M2 unexpectedly had double-digit nanomolar functional activity at the human receptor. It is known that taurine can be conjugated to bile acids and these conjugates may be hydrolyzed in the gut which allows for bile acid reabsorbtion.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Having observed a taurine conjugate metabolite, we hypothesized that <b>5c</b>, which like bile acids is also a highly lipophilic carboxylic acid, could also be a substrate for the same recirculation mechanism. To confirm that the <b>5c</b> taurine conjugate was a potential source of the observed recirculation, we synthesized M1 (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). When dosed orally to rats essentially identical plasma levels of <b>5c</b> were obtained compared to dosing of the parent compound. To eliminate the potential for a simple acidic hydrolysis of the conjugate in the GI tract to produce <b>5c</b> which could be absorbed directly, we incubated M1 in simulated gastric fluid at room temperature for 3 h with little chemical degradation to the parent. It is therefore highly likely that this conjugation and recirculation process contributes significantly to the favorable pharmacokinetic profile. Interestingly, no analogous conjugate was observed in vivo following dosing of <b>5g</b>, further highlighting the differences in behavior of the two compounds despite their very similar structures.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Preparation of M1 Metabolite<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) thionyl chloride; (b) taurine, 20% NaOH, 0 °C.</p></p></figure><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Metabolite profile of <b>5c</b> in the rat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last"><b>5c</b> is an orally bioavailable, non-prostanoid IP receptor agonist that is efficacious in the rat MCT model of PAH. It has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family, but a more modest 30-50-fold selectivity over the EP3 receptor. In our hands, its potency and efficacy are superior in vitro to <b>2</b> (the active metabolite of the clinical compound <b>1</b>) in in vitro measures of IP receptor mediated cAMP signaling and it is more potent in inhibiting ADP-induced aggregation in ex vivo platelet assays. <b>5c</b> is rapidly absorbed after oral administration in preclinical species, and its systemic clearance is primarily due to hepatic metabolism with probable enterohepatic recirculation. The elimination half-life ranges from 5 to 8 h in rodents to 10 and 18 h in dog and monkey, respectively. Exposure was so prolonged in the monkey that it may provide very low peak to trough plasma concentration ratios with repeated dosing in patients that could closely mimic continuous intravenous infusion. On the basis of these data, as well as an acceptable safety profile in IND-enabling studies, <b>5c</b> as its free acid solid form (which was subsequently given the USAN name ralinepag) was selected for further development for the treatment of PAH. Clinical studies are underway to determine if the excellent in vitro and PK profile can provide improvements in clinical efficacy over current therapies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div class="NLM_p">Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Bruker Avance-400 equipped with a QNP (Quad Nucleus Probe) or a BBI (Broad Band Inverse) and <i>z</i>-gradient. Chemical shifts are given in parts per million (ppm) with the residual solvent signal used as reference. NMR abbreviations are used as follows: s = singlet, d = doublet, dd = doublet of doublet, ddd = doublet of doublet of doublets, dt = doublet of triplet, t = triplet, tt = triplet of triplets, q = quartet, m = multiplet, br = broad. Microwave irradiations were carried out using either an Initiator or Initiator+ machine (Biotage). Thin-layer chromatography (TLC) was performed on silica gel 60 F<sub>254</sub> (Merck), preparatory thin-layer chromatography (prep TLC) was preformed on PK6F silica gel 60 A 1 mm plates (Whatman), and column chromatography was carried out either manually on a silica gel column using Kieselgel 60, 0.063–0.200 mm (Merck), or using prepacked columns for Isolera 1 (Biotage). Evaporation was done in vacuo on a Buchi rotary evaporator.</div><div class="NLM_p last">Test compound purity was measured by UV (254 nm) peak area over a 5 min 0–100% acetonitrile gradient elution. LCMS specs were the following. (1) PC: HPLC-pumps, LC-10AD VP, Shimadzu Inc.; HPLC system controller, SCL-10A VP, Shimadzu Inc.; UV detector, SPD-10A VP, Shimadzu Inc.; autosampler, CTC HTS, PAL, Leap Scientific; mass spectrometer, API 150EX with Turbo Ion Spray source, AB/MDS Sciex; software, Analyst 1.2. (2) Mac: HPLC-pumps, LC-8A VP, Shimadzu Inc.; HPLC system controller, SCL-10A VP; Shimadzu Inc.; UV detector, SPD-10A VP, Shimadzu Inc.; autosampler, 215 Liquid Handler, Gilson Inc.; mass spectrometer, API 150EX with Turbo Ion Spray source; AB/MDS Sciex Software, Masschrom 1.5.2. All test compounds were of greater than 95% purity by one or more of the above methods, and LC–MS purity for individual compounds is noted in the experimental.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Small Scale Synthesis Methods</h3><div class="NLM_p">Methods for the preparation of <i>trans</i> isomers are described. Identical methods were used for the <i>cis</i> isomers where prepared using (1<i>s</i>,4<i>s</i>)-cyclohexane-1,4-diyldimethanol in place of (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-((Diphenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5a</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 398.10 [M + H]<sup>+</sup>; purity, 98%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.10–1.42 (m, 8H), 1.53–1.60 (m, 2H), 1.70–1.87 (m, 2H), 3.91–3.93 (d, <i>J</i> = 4.2 Hz, 2H), 3.98 (s, 2H), 7.20–7.31 (m, 6H), 7.30–7.50 (m, 4H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Preparation of 2-(((1<i>s</i>,4<i>s</i>)-4-((Diphenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5b</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl 2-(((1<i>s</i>,4<i>s</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 398.45 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.15–1.40 (m, 8H), 1.50–1.62 (m, 2H), 1.75–1.81 (m, 2H), 3.90–3.92 (d, <i>J</i> = 4.3 Hz, 2H), 3.96 (s, 2H), 7.21–7.32 (m, 6H), 7.35–7.39 (m, 4H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Preparation of 2-(((1<i>s</i>,4<i>s</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5d</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl 2-(((1<i>s</i>,4<i>s</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-chloro-4-iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 432.1 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.28–1.53 (m, 8H), 1.60–1.81 (m, 2H), 3.29 (d, <i>J</i> = 7.07 Hz, 2H), 3.96 (s, 2H), 3.98 (d, <i>J</i> = 6.69 Hz, 2H), 7.24–7.33 (m, 5H), 7.36–7.48 (m, 4H).</div></div><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Methoxyphenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5e</b>). Step A: Preparation of ((1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl)methyl Phenylcarbamate</h4><div class="NLM_p last">To a solution of (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (5 g, 34.7 mmol) in pyridine at room temperature was added phenyl isocyanate (4.13 g, 34.7 mmol). The reaction mixture was stirred for 5 h, concentrated, and extracted with ethyl acetate. The extract was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel column chromatography to give the title compound (4.69 g, 51.5%). LCMS <i>m</i>/<i>z</i> = 264.43 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.81- 1.09 (m, 4H), 1.30–1.39 (m, 1H), 1.51–1.62 (m, 1H), 1.75–1.88 (m, 4H), 3.15–3.25 (d, <i>J</i> = 5.8 Hz, 2H), 3.82–3.95 (d, <i>J</i> = 6.56 Hz, 2H), 4.52 (t, <i>J</i> = 5.31 Hz, 1H), 6.29 (m, 1H), 7.30 (m, 2H), 7.48 (m, 2H), 9.62 (s, 1H).</div></div><div id="sec4_2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step B: Preparation of <i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((Phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate</h4><div class="NLM_p last">To a solution of ((1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl)methyl phenylcarbamate (2.5 g, 9.49 mmol) and diacetoxyrhodium (0.210 g, 0.475 mmol) in dichloromethane (50 mL) at 0°C was added dropwise a solution of <i>tert</i>-butyl 2-diazoacetate (1.350 g, 9.49 mmol) in dichloromethane (5 mL) over 20 min. After stirring for 30 min at room temperature, the solid was removed by filtration and the filtrate concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (3.32 g, 93%). LCMS <i>m</i>/<i>z</i> = 378.43 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.85–1.08(m, 4H), 1.42 (s, 9H), 1.41–1.62 (m, 2H), 1.78–1.81 (m, 4H), 3.25 (d, <i>J</i> = 6.3 Hz, 2H), 3.92 (d, <i>J</i> = 4.6 Hz, 2H), 6.29 (m, 1H), 7.31 (m, 2H), 7.48 (m, 2H), 9.62 (s, 1H).</div></div><div id="sec4_2_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step C: Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Methoxyphenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid</h4><div class="NLM_p last"><i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate: (50.0 mg, 0.132 mmol), copper(I) iodide (12.61 mg, 0.066 mmol), K<sub>3</sub>PO<sub>4</sub> (56.2 mg, 0.265 mmol), 4-methoxyphenyl iodide (31.0 mg, 0.132 mmol), and dioxane (1.6 mL) were added to a microwave vial. The reaction mixture was heated under microwave irradiation at 150 °C for 5 h. The cooled mixture was filtered through a plug of MgSO<sub>4</sub>. The solvent was evaporated, and the resulting oil was redissolved in HCl (4 M in dioxane, 1.987 mmol), and the mixture stirred overnight at room temperature After removal of the solvent, the residue was purified by preparative LCMS to provide the title compound as a white solid (12.2 mg, 21.6%). LCMS <i>m</i>/<i>z</i> = 428.4 [M + H]<sup>+</sup>, purity, 99%; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.92–0.97(m, 4H), 1.22–1.25 (m, 2H), 1.47–1.79 (m, 4H), 3.15 (d, <i>J</i> = 6.5 Hz, 2H), 3.79 (s, 3H), 3.95 (d, <i>J</i> = 6.0 Hz, 2H), 4.02 (s, 2H), 6.90–7.33 (m, 9H).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Preparation of 2-(((1<i>s</i>,4<i>s</i>)-4-(((4-Methoxyphenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5f</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl 2-(((1<i>s</i>,4<i>s</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-iodo-4-methoxybenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 428.2 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR(400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.34–1.56 (m, 8H), 1.70–1.88 (m, 2H), 3.31 (s, 3H), 3.39 (d, <i>J</i> = 7.07 Hz, 2H), 4.00 (d, <i>J</i> = 7.20 Hz, 2H), 4.11 (s, 2H), 6.94–7.01 (m, 2H), 7.23–7.31 (m, 4H), 7.42–7.49 (m, 3H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Preparation of 2-(((1<i>s</i>,4<i>s</i>)-4-(((3-Fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5h</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl 2-(((1<i>s</i>,4<i>s</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-fluoro-3-iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 416.4 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR(400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.28- 1.42 (m, 8H), 1.71 (s, 2H), 3.28 (d, <i>J</i> = 7.07 Hz, 2H), 3.96 (s, 2H), 3.99 (d, <i>J</i> = 6.44 Hz, 2H), 7.03- 7.11 (m, 2H), 7.20–7.33 (m, 4H), 7.37–7.43 (m, 3H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5i</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl-2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-chloro-3-iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 432.6 [M + H]<sup>+</sup>; purity, 99%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Methoxyphenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5j</b>)</h4><div class="NLM_p last">The title compound was obtained from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-bromo-3-methoxybenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 428.3 [M + H]<sup>+</sup>; purity, 98%; 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.81–0.98(m, 4H), 1.35–1.55 (m, 2H), 1.60–1.75 (m, 4H), 3.15 (d, <i>J</i> = 6.5 Hz, 2H), 3.50 (S, 2H), 3.75 (S, 3H), 3.95 (d, <i>J</i> = 6.0 Hz, 2H), 6.80–6.95 (m, 4H), 7.25–7.45 (m, 5H).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-((Phenyl(<i>p</i>-tolyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5k</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy acetate and 1-iodo-4-methylbenzene using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 412.2 [M + H]<sup>+</sup> purity, 99%.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5l</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from <i>tert</i>-butyl-2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-fluoro-4-iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 416.5 [M + H]<sup>+</sup>; purity, 99%.; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 0.79–1.08 (m, 4H), 1.45–1.60 (m, 2H), 1.61–1.73 (m, 2H), 1.77–1.89 (m, 2H), 3.29 (d, <i>J</i> = 6.57 Hz, 2H), 15 3.83 (s, 2H), 3.97 (d, <i>J</i> = 6.06 Hz, 2H), 7.07–7.14 (m, 2H), 7.21–7.34 (m, 5H), 7.35–7.41 (m, 2H).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chloro-3-fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5m</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-chloro-2-fluoro-4-iodobenzene, using a similar method to the one described in compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 450.1 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 0.69–0.91 (m, 4H), 1.08–1.31 (m, 1H), 1.32–1.48 (m, 1H), 1.48–1.64 (m, 2H), 1.64–1.81 (m, 2H), 3.17 (d, <i>J</i> = 6.57 Hz, 2H), 3.71 (s, 2H), 3.87 (d, <i>J</i> = 6.06 Hz, 2H), 6.94 (ddd, <i>J</i> = 8.75, 2.43, 1.20 Hz, 1H), 7.14–7.24 (m, 4H), 7.27–7.34 (m, 3H).</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Chloro-4-fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5n</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 2-chloro-1-fluoro-4-iodobenzene, using a similar method to the one described in compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 450.2 [M + H]<sup>+</sup>; purity, 99%.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3,4-Difluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5o</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((phenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1,2-difluoro-4-iodobenzene, using a similar method to the one described in compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 434.5 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 0.93–1.11 (m, 4H), 1.52–1.68 (m,2H), 1.67–1.81 (m, 2H), 1.84–1.98 (m, 2H), 3.36 (d, <i>J</i> = 6.44 Hz, 2H), 3.90 (s, 2H), 4.05 (d, <i>J</i> = 6.06 Hz, 2H), 7.10–7.18 (m, 1H), 7.27–7.42 (m, 5H), 7.45–7.53 (m, 2H).</div></div><div id="sec4_2_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Fluorophenyl)(4-methoxyphenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5p</b>). Step A: Preparation of <i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl)methoxy)acetate</h4><div class="NLM_p last">To a solution of (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (5.0 g, 34.7 mmol) in benzene (20 mL) at room temperature were added tetrabutylammonium iodide (6.40 g, 17.34 mmol) and 50% aqueous NaOH (10 mL, 34.7 mmol). The mixture was stirred vigorously for 5 min, and then <i>tert</i>-butyl 2-bromoacetate (5.63 mL, 38.1 mmol) was added. The reaction was stirred vigorously for a further 2 h. The mixture was partitioned between 50% aqueous NaOH (100 mL) and EtOAc (100 mL). The aqueous layer was extracted again with EtOAc (100 mL). The combined organic layer was dried and concentrated. The residue was purified by silica gel column chromatography to provide the title compound as a colorless oil (3.96g, 44%). LCMS <i>m</i>/<i>z</i> = 259.3 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 0.89–1.06 (m, 4H), 1.47 (s, 9H), 1.55–1.68 (m, 2H), 1.76–1.98 (m, 4H), 3.32 (d, <i>J</i> = 6.57 Hz, 2H), 3.45 (d, <i>J</i> = 6.32 Hz, 2H), 3.93 (s, 2H).</div></div><div id="sec4_2_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step B: Preparation of <i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((3-Fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl)methoxy)acetate (1.0 g, 3.87 mmol) and pyridine (0.438 mL, 5.42 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added 3-fluorophenyl isocyanate (0.480 mL, 4.26 mmol), and the reaction was stirred at room temperature overnight. The reaction was then heated to reflux for 5 h. After removal of the solvent, the residue was purified by silica gel column chromatography to yield the title compound as a white solid (1.12 g). LCMS <i>m</i>/<i>z</i> = 340.4 [M – <i>tert</i>-butyl + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 0.85–1.04 (m, 4H), 1.41 (s, 9H), 1.51–1.64 (m, 2H), 1.69–1.87 (m, 4H), 3.26 (d, <i>J</i> = 6.32 Hz, 2H), 3.87 (s, 2H), 3.92 (d, <i>J</i> = 6.57 Hz, 2H), 6.57 (s, 1H), 6.68 (dt, <i>J</i> = 8.34, 2.53 Hz, 1H), 6.94 (d, <i>J</i> = 8.59 Hz, 1H), 7.13–7.18 (m, 1H), 7.20–7.28 (m, 1H).</div></div><div id="sec4_2_14_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step C: Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Fluorophenyl)(4-methoxyphenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid</h4><div class="NLM_p last">The title compound was obtained as a white solid from 1-iodo-4-methoxybenzene and <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((3-fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 446.5 [M + H]<sup>+.</sup>; purity, 99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.86 (t, <i>J</i> = 11 Hz, 4H), 1.39 (s, 2H), 1.54–1.62 (m, 2H), 1.64–1.74 (m, 2H), 3.23 (d, <i>J</i> = 6.32 Hz, 2H), 3.76 (s, 3H), 3.89 (d, <i>J</i> = 6.19 Hz, 2H), 3.94 (s, 2H), 6.91–6.98 (m, 2H), 6.99–7.07 (m, 2H), 7.17–7.26 (m, 3H), 7.36 (dt, <i>J</i> = 8.18, 6.88 Hz, 1H), 12.52 (br s, 1H).</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(3-fluorophenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5q</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from 1-chloro-4-iodobenzene and <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((3-fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 450.5 [M + H]<sup>+</sup>. purity, 99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.77–0.98 (m, 4H), 1.34–1.42 (m, 1H), 1.42–1.52 (m, 1H), 1.53–1.63 (m, 2H), 1.63–1.75 (m, 2H), 3.23 (d, <i>J</i> = 6.44 Hz, 2H), 3.91 (d, <i>J</i> = 6.06 Hz, 2H), 3.94 (s, 2H), 7.04–7.14 (m, 2H), 7.23–7.28 (m, 1H), 7.29–7.36 (m, 2H), 7.36–7.42 (m, 1H), 7.42–7.49 (m, 2H), 12.52 (br s, 1H).</div></div><div id="sec4_2_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-((Bis(4-fluorophenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>5r</b>). Step A: Preparation of Methyl 4-Fluoro-2-((1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl)phenylcarbamate</h4><div class="NLM_p last">4-Fluorophenyl isocyanate (4.75 g, 34.7 mmol), (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (5.0 g, 34.7 mmol), and pyridine (3.93 mL, 48.5 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The reaction mixture was stirred at room temperature overnight. After removal of the solvent, the residue was purified by silica gel column chromatography to yield the title compound as a white solid (4.92 g, 50%). LCMS <i>m</i>/<i>z</i> = 282.4 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.81–1.07 (m, 4H), 1.25–1.38 (m, 1H), 1.49–1.64 (m, 1H), 1.72–1.82 (m, 4H), 3.19–3.24 (m, 2H), 3.89 (d, <i>J</i> = 6.57 Hz, 2H), 4.34 (t, <i>J</i> = 5.31 Hz, 1H), 7.06–7.15 (m, 2H), 7.46 (dd, <i>J</i> = 8.97, 4.93 Hz, 2H), 10 9.61 (s, 1H).</div></div><div id="sec4_2_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step B: Preparation of <i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((4-Fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate</h4><div class="NLM_p last">To a solution of methyl 4-fluoro-2-((1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl)phenylcarbamate (2.0 g, 7.11 mmol) and rhodium(II) acetate (0.157 g, 0.355 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C was slowly added <i>tert</i>-butyl 2-diazoacetate (1.084 mL, 7.82 mmol) predissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) via an addition funnel. The reaction was stirred at 0 °C for 1 h and then at room temperature for another 1 h. After removal of the solvent, the residue was purified by silica gel column chromatography to yield the title compound as a tan solid (1.9 g, 61%). LCMS <i>m</i>/<i>z</i> = 340.4 [M – <i>tert</i>-butyl + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.97 (d, <i>J</i> = 10.36 Hz, 4H), 1.42 (s, 9H), 1.44–1.53 (m, 1H), 1.54–1.64 (m, 1H), 1.72–1.82 (m, 4H), 3.26 (d, <i>J</i> = 6.32 Hz, 2H), 3.90 (d, <i>J</i> = 6.57 Hz, 2H), 3.92 (s, 2H), 7.06–7.15 (m, 2H), 7.46 (dd, <i>J</i> = 8.84, 4.93 Hz, 2H), 9.61 (s, 1H).</div></div><div id="sec4_2_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step C: Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-((Bis(4-fluorophenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid</h4><div class="NLM_p last">The title compound was obtained as a white solid from <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((4-fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate and 1-fluoro-4-iodobenzene, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 434.5 [M + H]<sup>+</sup>; purity, 99%.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Fluorophenyl)(3-fluorophenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5s</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from 1-chloro-4-iodobenzene and <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((3-fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 434.4. [M + H]<sup>+</sup>; purity, 99%.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chloro-3-fluorophenyl)(3-fluorophenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5t</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid from 1-chloro-2-fluoro-4-iodobenzene and <i>tert</i>-butyl 2-(((1<i>r</i>,4<i>r</i>)-4-((3-fluorophenylcarbamoyloxy)methyl)cyclohexyl)methoxy)acetate, using a similar method to the one described for compound <b>5e</b>. LCMS <i>m</i>/<i>z</i> = 468.5. [M + H]<sup>+</sup>; purity, 99%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> First Scale-Up Route</h3><div id="sec4_3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Preparation of Sodium 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>5c</b>). Step A Preparation of 4-Chlorophenyl(phenyl)carbamic Chloride (<b>12c</b>, X = Cl, R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl)</h4><div class="NLM_p last">4-Chloro-<i>N</i>-phenylaniline (10 g, 49.1 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The solution was cooled on an ice bath (0 °C), and then triphosgene (16.03 g, 54.0 mmol) was added. Pyridine (5.56 mL, 68.7 mmol) predissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added slowly via addition funnel to the reaction mixture (exothermic; the solution went from a green color to an orange-yellow color). Upon complete addition, the reaction was stirred on the ice bath for another 15 min and then warmed to room temperature and stirred for an hour. After this time, the reaction was complete as judged by TLC. The reaction was again cooled on an ice bath and quenched by the slow addition of H<sub>2</sub>O (20 mL; exothermic; reaction bubbled vigorously). The reaction was extracted (100 mL each of H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>). The aqueous layer was extracted again with CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The combined organic layers were dried, concentrated, and the product was purified by chromatography (0, 10, 20, 30, 40% CH<sub>2</sub>Cl<sub>2</sub>/hexanes step gradient) to provide 4-chlorophenyl(phenyl)carbamic chloride (12.34 g, 45.9 mmol, 93% yield) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.31–7.81 (m).</div></div><div id="sec4_3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Step B: Preparation of ((1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl)methyl 4-Chlorophenyl(phenyl)carbamate (<b>11</b>, R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl)</h4><div class="NLM_p last">4-Chlorophenyl(phenyl)carbamic chloride (12.34 g, 46.4 mmol) and (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (6.69 g, 46.4 mmol) were dissolved in pyridine (50 mL, 618 mmol). The reaction mixture was heated to reflux overnight and then cooled and concentrated under reduced pressure. The residue was resuspended in Et<sub>2</sub>O/EtOAc (50:50), filtered and the filtered solid washed with Et<sub>2</sub>O/EtOAc (50:50). The filtrate was partitioned between 1 M HCl (200 mL) and EtOAc (200 mL). The aqueous layer was extracted again with EtOAc (100 mL). The organic layers were combined and washed with H<sub>2</sub>O (200 mL), dried, and concentrated. The residue was purified by silica gel column chromatography to provide the title compound as a light pink colored solid (10.4 g, 60%). LCMS <i>m</i>/<i>z</i> = 374.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.73–0.92 (m, 4H), 1.13–1.27 (m, 1H), 1.36-l.48 (m, 1H), 1.53–1.62 (m, 2H), 1.62–1.73 (m, 2H),3.17 (d, <i>J</i> = 6.19 Hz, 2H), 3.89 (d, <i>J</i> = 6.06 Hz, 2H), 4.29 (br s, 1H), 7.23–7.32 (m, 5H), 7.34–7.45 (m, 4H).</div></div><div id="sec4_3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Step C: Preparation of <i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>9</b>, R = <sup><i>t</i></sup>Bu, R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl)</h4><div class="NLM_p last">((1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl)methyl4-chlorophenyl(phenyl)carbamate (8.9 g, 23.80 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). Diacetoxyrhodium (0.526 g, 1.190 mmol) was added, and the reaction was cooled on an ice bath. <i>tert</i>-Butyl 2-diazoacetate (3.63 mL, 26.2 mmol) predissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added slowly to the reaction via an addition funnel. The reaction was stirred in an ice bath for 1 h, warmed to room temperature, and stirred for an additional 1 h. After removal of the solvent, the residue was purified by silica gel column chromatography to provide the title compound as a colorless oil (8.8 g, 75%). LCMS <i>m</i>/<i>z</i> = 432.6 [M – <i>tert</i>-butyl group + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.77–0.95 (m, 4H), 1.33–1.50 (m, 2H), 1.42 (s, 9H), 1.52–1.62 (m, 2H), 1.63–1.75 (m, 2H), 3.22 (d, <i>J</i> = 6.32 Hz, 2H), 3.83–3.93 (m, 4H), 7.23–7.32 (rn, 5H), 7.35–7.44 (m, 4H).</div></div><div id="sec4_3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Step D: Preparation of Sodium 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>5c</b>, Sodium Salt)</h4><div class="NLM_p last"><i>tert</i>-Butyl 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (8.8 g, 18.03 mmol) was dissolved in HCl (4 M in dioxane, 100 mL, 400 mmol). The reaction was stirred at room temperature overnight and concentrated under reduced pressure to provide an oil. The oil was partitioned between H<sub>2</sub>O (100 mL) and EtOAc (100 mL). The aqueous layer was extracted again with EtOAc (100 mL). The combined organic layer was washed with H<sub>2</sub>O (150 mL), dried, and concentrated to yield a light yellow oil. The oil was dissolved in a minimal amount of MeOH (10–20 mL) and cooled in an ice bath. NaOH (1M, 27.0 mL, 27.0 mmol) was added with stirring during which time a white solid precipitate was formed. The mixture was diluted with H<sub>2</sub>O (20 mL). The solid was collected by filtration and washed with cold H<sub>2</sub>O (20 mL). The resulting white solid was dried in a vacuum oven (60 °C overnight) to provide the title compound (7.7 g, 98%). LCMS <i>m</i>/<i>z</i> = 432.5 [M + H]<sup>+</sup>; purity, 99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.73–0.93 (m, 4H), 1.28–1.40 (m, 1H), 1.40–1.50 (m, 1H), 1.50–1.61 (m, 2H), 1.63–1.77 (m, 2H), 3.16 (d, <i>J</i> = 6.57 Hz, 2H), 3.47 (s, 2H), 3.89 (d, <i>J</i> = 6.06 Hz, 2H), 7.23–7.32 (m, 5H), 7.35–7.44 (m, 4H).</div></div><div id="sec4_3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Preparation of Sodium 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>5g</b>). Step A: Preparation of 3-Fluoro-<i>N</i>-phenylaniline (<b>11</b>, R<sup>1</sup> = H, R<sup>2</sup> = 3-F)</h4><div class="NLM_p last">In a 3 L, three-neck flask equipped with mechanical stirring, a solution of 3-fluoroaniline (75 g, 675 mmol), bromobenzene (73 mL, 690 mmol), and dichloro[1,1′-20-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (15 g, 18 mmol) in anhydrous toluene (1.3 L) containing sodium <i>tert</i>-butoxide (130 g, 1.35 mol) was heated at 105 °C for 3 h. The reaction mixture was then cooled to 80 °C and quenched by gradually pouring the reaction mixture into ice/water (1 L). The aqueous layer was removed and was then extracted with an additional volume of toluene (300 mL). The organic extracts were combined, rinsed with brine, dried over MgSO<sub>4</sub>, and passed through a silica plug (1.3 kg), eluting with toluene. The solvent was removed to give a dark amber oil (86 g, 68%). LCMS <i>m</i>/<i>z</i> = 188 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.45 (t, <i>J</i> = 8.5 Hz, 1H), 6.62–6.66 (m, 2H), 6.87 (t, <i>J</i> = 7.2 Hz, 1H), 6.98 (d, <i>J</i> = 7.6 Hz, 2H), 7.05 (q, <i>J</i> = 7.5 Hz, 1H), 7.17 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Step B: Preparation of 3-Fluorophenyl(phenyl)carbamic Chloride (<b>12</b>, X = Cl, R<sup>1</sup> = H, R<sup>2</sup> = 3-F)</h4><div class="NLM_p last">A 3 L three-neck mechanically stirred flask under N<sub>2</sub> containing a solution of 3-fluoro-<i>N</i>-phenylaniline (86 g, 460 mmol) in 1.2 L of dichloromethane was cooled in an ice bath to 0 °C, and then triphosgene (150 g, 505 mmol) was added. A solution of pyridine (52 mL, 640 mmol) in dichloromethane (200 mL) was added in a dropwise fashion. Initial addition resulted in a temperature spike to 25 °C after the first 10 mL had been added over 10 min. The addition was paused, and the reaction mixture was stirred for 1 h while recooling to 5 °C. Addition of the pyridine solution was again commenced at a rate of 5 mL/min, at which an internal reaction temperature of 5–10 °C could be maintained. After addition was complete (about 1 h), the reaction had proceeded to completion and was quenched by the slow addition of ice–water (500 g). Gas was passed through a 20% sodium hydroxide trap until all gas evolution had ceased (about 3 h). The aqueous layer was removed and was then extracted with an additional 300 mL of dichloromethane. The organic extracts were combined, dried over MgSO<sub>4</sub>, and the solvent was removed. Clean product was readily isolated as a viscous, pink oil, which gradually formed a pale pink solid upon seeding with crystals. LCMS <i>m</i>/<i>z</i> = 250.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.00–7.07 (m, 1H), 7.10 (d, <i>J</i> = 9.6 Hz, 1H), 7.15 (d, <i>J</i> = 8.1 Hz, 1H), 7.35 (d, <i>J</i> = 7.7 Hz, 2H), 7.35–7.41 (m, 2H), 7.42–7.48 (m, 2H).</div></div><div id="sec4_3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step C: Preparation of 4-(Dimethylamino)-1-((3-fluorophenyl)(phenyl)carbamoyl)pyridinium Chloride (<b>12</b>, X = DMAP, R<sup>1</sup> = H, R<sup>2</sup> = 3-F)</h4><div class="NLM_p last">To a solution of crude 3-fluorophenyl(phenyl)carbamic chloride (62.4 g, 250 mmol) in acetonitrile (500 mL) in a 2 L mechanically stirred three-neck flask was added a solution of 4-dimethylaminopyridine (30.5 g, 250 mmol) in 500 mL acetonitrile. The flask warmed slightly as crystallization began to occur and then cooled again to ambient temperature. The resulting suspension was stirred overnight, cooled to 10 °C in an ice bath and the precipitate filtered, rinsing with cold acetonitrile (100 mL) to provide the title compound as a fine, white solid (88.27 g). LCMS <i>m</i>/<i>z</i> = 336. [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 3.29 (s, 6H), 6.92 (d, <i>J</i> = 8.1 Hz, 2H), 7.11 (t, <i>J</i> = 8.6 Hz, lH), 7.16 (d, <i>J</i> = 8.8 Hz, lH), 7.21 (d, <i>J</i> = 9.5 Hz, lH), 7.33–7.38 (m, 3H), 7.41–7.47 (m, 3H), 8.37 (d, <i>J</i> = 8.1 Hz, 2H).</div></div><div id="sec4_3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Step D: Preparation of ((1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl)methyl-3-fluorophenyl(phenyl)carbamate (<b>13</b>, R<sup>1</sup> = H, R<sup>2</sup> = 3-F)</h4><div class="NLM_p last">A suspension of 4-(dimethylamino)-1-((3-fluorophenyl)(phenyl)carbamoyl)pyridinium chloride (88.25 g, 237 mmol), (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (137 g, 950 mmol), and 4-dimethylaminopyridine (29.0 g, 237 mmol) in acetonitrile (1 L) was heated at 53 °C for 18 h. Upon cooling, the solvent was removed, and the residue was taken up in isopropyl acetate (500 mL) and 1 M HCl (500 mL), heated to suspend all solids, and then filtered through glass fiber filter paper to attempt to remove a sparingly soluble bis-carbamate impurity. The aqueous filtrate was discarded, and the organic filtrate was washed with an additional 500 mL of 1 N HCl, followed by water (5 × 500 mL). Heptane (100 mL) was added to the organic phase, which was further washed with water (2 × 500 mL) and brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated to dryness. The residue was taken up in isopropyl acetate (100 mL), and heptane (300 mL) was added. Crystals gradually formed over 1 h, providing a white precipitate, which was collected by filtration, and washed with 25% isopropyl acetate/heptane (100 mL). The filtrate was concentrated to dryness, and the residue was taken up in hot 25% isopropyl acetate/heptane (100 mL) and filtered hot. As the filtrate cooled, more solids precipitated, which were collected by filtration and combined with the first crop. This material still contained about 5% bis-carbamate byproduct, which could not be readily removed by filtration. The solid was then taken up in dichloromethane (200 mL) and subjected to plug filtration over 1.6 kg of silica gel, eluting the product with 20% ethyl acetate/dichloromethane to provide the title compound as a white solid (71 g, 83%) and the remaining bis-carbamate with dichloromethane. LCMS <i>m</i>/<i>z</i> = 358. [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 0.91–0.98 (m, 4H), 1.35–1.44 (m, 1H), 1.54–1.60 (m, 1H), 1.68–1.73 (m, 2H), 1.79–1.83 (m, 2H), 3.45 (d, <i>J</i> = 6.4 Hz, 2H), 4.01 (d, <i>J</i> = 6.4 Hz, 2H), 6.91 (t, <i>J</i> = 7.6 Hz, 1H), 7.04 (d, <i>J</i> = 8.6 Hz, 2H), 7.22–7.30 (m, 4H), 7.38 (t, <i>J</i> = 7.8 Hz, 2H).</div></div><div id="sec4_3_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Step E: Preparation of Ethyl 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Fluorophenyl)phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>7</b>, R = Et, R<sup>1</sup> = H, R<sup>2</sup> = 3-F)</h4><div class="NLM_p last">In a 250 mL three-neck reactor equipped with a stirrer, a thermocouple, a cooling bath, an addition funnel, and a nitrogen inlet was placed ((1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl)methyl-3-fluorophenyl(phenyl)carbamate (8 g, 22.38 mmol). This was dissolved in dichloromethane (150 mL). The mixture was cooled and stirred well at 4 °C in an isopropanol/ice bath. Diacetoxyrhodium (0.5 g, 1.12 mmol) was added. After the addition was complete, ethyl diazoacetate (3.69 g, 32.34 mmol) was dissolved in dichloromethane (30 mL) and added to the reaction mixture keeping the temperature below 10 °C. After addition, the reaction mixture was warmed to 30 °C and the progress of the reaction was followed by LCMS. On the basis of the LCMS in-process control, further batches of ethyl diazoacetate (0.63 g, 5.52 mmol, followed by 0.710 g, 6.22 mmol dissolved in dichloromethane (15 mL)) were added separately at 25 °C. The reaction mixture was stirred at 30 °C until LCMS showed complete consumption of the starting material. The reaction mixture was diluted with water (100 mL), and the mixture was filtered through a bed of Celite (35 g) to remove the catalyst. The organic layer was then separated and dried over magnesium sulfate (15 g) and filtered. The solvent was removed to provide the title compound as an oil (9.9 g), which still contained a small amount of ethyl diazoacetate and was used without further purification. LCMS <i>m</i>/<i>z</i> = 444.5 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.82–0.96 (m, 4H), 1.22 (t, <i>J</i> = 7.07 Hz, 3H), 1.27 (t, <i>J</i> = 7.14 Hz, 1H), 1.37–1.53 (m, 2H), 1.57–1.78 (m, 4H), 3.26 (d, <i>J</i> = 6.32 Hz, 2H), 3.94 (d, <i>J</i> = 6.06 Hz, 2H), 4.06 (s, 2H), 4.14 (q, <i>J</i> = 7.07 Hz, 3H), 4.23 (q, <i>J</i> = 7.07 Hz, 1H), 7.05–7.11 (m, 2H), 7.24 (dt, <i>J</i> = 10.64, 2.26 Hz, 1H), 7.28–7.35 (m, 3H), 7.36–7.45 (m, 3H).</div></div><div id="sec4_3_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step F: Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (<b>5g</b>, Free Acid)</h4><div class="NLM_p last">In a 500 mL, three-neck reactor equipped with a stirrer, a thermocouple, a heating oil bath, an addition funnel, and a nitrogen inlet was placed ethyl 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (9.9 g, 22.32 mmol), which was dissolved in acetonitrile (150 mL). To this mixture lithium bromide (19.58 g, 225.00 mmol) was added. After the addition was complete, triethylamine (6.84 g, 67.6 mmol) was added and the reaction mixture was heated at 70 °C. The progress of the reaction was followed by LCMS. On the basis of the LCMS, the starting material was consumed in 2 h. Solvent was removed, and the reaction mixture was diluted with water (200 mL) and made acidic with hydrochloric acid (3 M, 7.8 mL). The precipitated solids were filtered, and the wet solid was dissolved in isopropyl acetate (200 mL). The isopropyl acetate solution was dried over magnesium sulfate (15 g), filtered, and the solvent was removed. The residue was dried in a vacuum oven to provide the title compound (9.2 g, 95%). LCMS <i>m</i>/<i>z</i> = 416.4 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.81–0.96 (m, 4H), 1.36–1.53 (m, 2H), 1.55–1.77 (m, 4H), 3.25 (d, <i>J</i> = 6.44 Hz, 2H), 3.93 (d, <i>J</i> = 5.94 Hz, 2H), 3.97 (s, 2H), 7.05–7.13 (m, 2H), 7.24 (dt, <i>J</i> = 10.64, 2.26 Hz, 1H), 7.28–7.36 (m, 3H), 7.37–7.46 (m, 3H), 12.53 (br s, 1 H)</div></div><div id="sec4_3_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Step G: Preparation of 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-Fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid Sodium Salt (<b>5g</b>, Sodium Salt)</h4><div class="NLM_p last">In a 500 mL, three-neck reactor equipped with a stirrer, a thermocouple, a heating oil bath, an addition funnel, and a nitrogen inlet was placed 2-(((1<i>r</i>,4<i>r</i>)-4-(((3-fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (9.2 g, 22.83 mmol) and 2-propanol (100 mL). The reaction mixture was heated at 30 °C (bath temperature) until all of the acid was dissolved completely. To the orange solution, sodium hydroxide (1 M, 22 mL, 22 mmol) was added slowly keeping the internal temperature around 25 °C. The sodium salt separated out as crystals. The thick slurry was stirred at 25 °C for 2 h and then cooled in an ice–water bath for 20–40 min. The solids were filtered and dried in a vacuum oven at 40 °C overnight until most of the residual 2-propanol was removed to provide the title compound (7.4 g, 74%). LCMS <i>m</i>/<i>z</i> = 416.5 [M + H]<sup>+</sup>; purity, 99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.77–0.95 (m, 4H), 1.34–1.53 (m, 2H), 1.55–1.75 (m, 4H), 3.19 (d, <i>J</i> = 6.44 Hz, 2H), 3.52 (s, 2H), 3.93 (d, <i>J</i> = 5.94 Hz, 2H), 7.05–7.13 (m, 2H), 7.24 (dt, <i>J</i> = 10.64, 2.26 Hz, 1H), 7.28–7.35 (m, 3H), 7.37–7.46 (m, 3H).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Second Scale-Up Route</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step A: Preparation of ((1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl)methyl 4-chlorophenyl(phenyl)carbamate (<b>13</b> R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl)</h4><div class="NLM_p">A solution of (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol in acetonitrile was prepared by charging (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (4.22 kg) and acetonitrile (13.37 kg) to a 50 L glass lined reactor equipped with overhead agitation, jacket temperature control, and a nitrogen inlet. The reactor contents were stirred at 163 rpm and heated to 65 °C for 1 h to dissolve most of the (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol. The mixture was cooled to 45 °C and transferred to a 20 L fluorinated high density polyethylene (HDPE) carboy for addition to <b>12</b> (X = CDI, R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) at a later time.</div><div class="NLM_p"><b>11</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl, 1.71 kg), K<sub>3</sub>PO<sub>4</sub> (0.53 kg), carbonyl diimidazole (CDI, 1.49 kg), and acetonitrile (6.69 kg) were charged to a 50 L glass lined reactor equipped with overhead agitation, jacket temperature control, and a nitrogen inlet. The reactor contents were stirred at 175 rpm and heated to 65–70 °C for 4.5 h, after which conversion of <b>11</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) to <b>12</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) was verified to be greater than 98.0% by HPLC peak area. The reaction mixture was cooled to less than 40 °C and the (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol solution prepared earlier added to the mixture. The reactor contents were stirred at 178 rpm and heated at 65–70 °C for 5 h, after which conversion was 99.6% by HPLC peak area</div><div class="NLM_p">The 50 L reactor contents were filtered, and the filter cake was rinsed with acetonitrile (1.10 kg). The filtrate was transferred back to the reactor. Most of the acetonitrile (18.48 kg) was then removed at an internal temperature of less than 40 °C by vacuum distillation at 80 mmHg. Water (5.67 kg) was added to the 50 L reactor, and approximately 1.55 kg of water/acetonitrile mixture was then removed by vacuum distillation at an internal temperature of less than 40 °C and 70 mmHg.</div><div class="NLM_p last">Further water (5.68 kg) was then added to the 50 L reactor, and the product precipitated during the addition. The resulting mixture was stirred at 20–25 °C for 4 h. The precipitated product was filtered and washed in two portions with aqueous acetonitrile (1.68 kg of acetonitrile dissolved in 6.39 kg of water). The product was vacuum-dried at ≤60 °C to a loss on drying value of ≤2.0 wt %. <b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl, 2.29 kg) was thus obtained in 73% yield (over 2 telescoped steps) and 98.1% purity by HPLC peak area.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Step B: Preparation of Sodium 2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetate (<b>5c</b>)</h4><div class="NLM_p"><b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl, 1.70 kg), tetrabutylammonium bromide (0.45 kg), and toluene (8.82 kg) were charged to a 50 L glass lined reactor equipped with overhead agitation, jacket temperature control, and a nitrogen inlet. After <b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) had dissolved by stirring at 20 °C for 1 h, <i>tert</i>-butyl bromoacetate (1.33 kg) was added at 20 °C to the reaction mixture. The jacket temperature was set to −5 °C, and 50 wt % aq sodium hydroxide (15.31 kg) was added sufficiently slowly to maintain the stirred reaction mixture at 2–10 °C with reactor jacket cooling. The mixture was stirred at that temperature for 7.2 h. Conversion of <b>13</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) to <b>9</b> (R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) was then verified to be 93.6% by HPLC peak area.</div><div class="NLM_p">Thereafter, the reactor contents were heated at 45–51 °C for 3.0 h. Conversion of <b>9</b> (R = <sup><i>t</i></sup>Bu, R<sup>1</sup> = H, R<sup>2</sup> = 4-Cl) to <b>5c</b> was then verified to be 99.8% by HPLC peak area. The reactor contents were then cooled to 42 °C, and hydrochloric acid, conc (20.04 kg), was added to the mixture slowly so as to maintain an internal temperature at ≤45 °C. The mixture was filtered to remove the solid sodium chloride from the reactor, and the filtrate was collected in clean carboys.</div><div class="NLM_p">After cleaning the reactor with water, filtrate from the carboys was transferred back to the reactor and the phases separated. The aqueous layer was extracted with toluene (4.43 kg), and the phases separated again. The toluene layers were combined and the mixture was vacuum distilled at 42 °C and 5 mmHg to remove toluene (7.5 kg). IPA (13.36 kg) was charged to the reactor, and the resulting solution was vacuum distilled at 31.4 °C and 5.7 mmHg to remove solvent (16.98 kg). Acetone (11.10 kg) and water (3.08 kg) were charged to the reactor and the reactor contents stirred at 20 °C. Thereafter, 12.5% sodium hydroxide (1.25 kg; made by diluting 50 wt % sodium hydroxide with water) was added to the reactor contents to a pH of 9 to 10. The mixture was agitated at 173 rpm for 1 h at 0 °C. The resulting precipitated product was filtered, and the filter cake was washed with acetone (5.58 kg).</div><div class="NLM_p">The filter cake was transferred to the reactor using acetone (12.59 kg) and water (4.56 kg), and the mixture was heated at 50 °C for 1.5 h. The resulting mixture was filtered through a sintered glass filter and the filtrate transferred to the clean reactor. Acetone (3.23 kg) was added, and the mixture was stirred for 15.7 h at 1.9 °C. The reactor contents were filtered, and the filter cake was washed with acetone (4.00 kg). The filter cake was then transferred back to the reactor with the aid of water (17.01 kg), and 2 N hydrochloric acid (0.90 kg; made by diluting concentrated HCl with water) was added to the reactor contents to a pH of 2. The reactor contents were stirred at 150 rpm and 16 °C for 23.5 h.</div><div class="NLM_p last">The product slurry was collected by filtration, washed with two portions of water (25.54 kg total), dried at 65–70 °C under vacuum for 72.1 h, and finally sieved through a 1.18 mesh screen. <b>5c</b> (1.16 kg) was thus obtained in 59% yield (over two telescoped steps) and in 99.5% purity by HPLC peak area.</div></div><div id="sec4_4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Preparation of 2-(2-(((1<i>r</i>,4<i>r</i>)-4-(((4-Chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetamido)ethanesulfonic Acid (<b>M1</b>)</h4><div class="NLM_p"><b>5c</b> (sodium salt, 10 g, 23.15 mmol) was dissolved in thionyl chloride (40 mL) and the mixture heated at 70 °C for 3 h. The excess thionyl chloride was removed under reduced pressure, and the residual orange solids were dissolved in Ddioxane (100 mL). Taurine (2.9 g, 23.15 mmol) was dissolved in 20% sodium hydroxide (25 mL), cooled to 0 °C, and treated dropwise with the dioxane solution of the acid chloride while keeping the internal temperature of the mixture below 5 °C during addition. When addition was complete, the mixture was allowed to warm to room temperature and then stirred overnight.</div><div class="NLM_p">LC/MS indicated formation of the title compound and some unreacted taurine and <b>3c</b>. The crude mixture was concentrated to remove dioxane, the resulting yellow solid was cooled, and a solution of 1 N HCl (150 mL) was added. The fine solids were filtered (very slow filtration) and washed with 1 N HCl (950 mL). The solids were dissolved in ethanol and concentrated to remove residual water. More ethanol (150 mL) was added and the resultant suspension filtered to remove the excess taurine. The solids were suspended in acetonitrile (200 mL) and stirred overnight. The mixture was then filtered and the resultant solid product dried in a vacuum oven at 50 °C overnight to provide a pale yellow solid (9.62g, 77%). HPLC analysis showed the product to consist of >97% of the title compound and 1.2% of <b>5c</b> as well as some other unidentified minor impurities.</div><div class="NLM_p last">In order to fully evaluate the receptor properties of M1 without any contamination with the known active compound <b>5c</b>, a small sample was purified by preparative HPLC. Thus, the solid (20 mg) was dissolved in water and purified by preparative RP-HPLC (solvent A, 0.05% TFA; solvent B, 0.05% TFA in acetonitrile, gradient 15–90% B in 20 min, flow rate 20 mL/min, column Alltech Prevail C18, 5 μm, 22 mm × 100 mm, autosampler/fraction collector Gilson 215; HPLC, Shimadzu SCL-10 Avp controller, LC-8ADvp pumps; mass spectrometer, Sciex API 150 EX) with mass-triggered fraction collection and the pure product containing fractions lyophilized. The resulting product M1 (∼9 mg) contained less than 0.06% <b>5c</b> by HPLC. Exact mass calcd for C<sub>25</sub>H<sub>31</sub>ClN<sub>2</sub>O<sub>7</sub>S, 538.2; found, LCMS <i>m</i>/<i>z</i> 539.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 0.78–0.97 (m, 4H), 1.37–1.52 (m, 2H), 1.52–1.62 (m, 2H), 1.67–1.77 (m, 2H), 2.54 (t, <i>J</i> = 6.44 Hz, 2H), 3.21 (d, <i>J</i> = 6.32 Hz, 2H), 3.37 (q, <i>J</i> = 5.81 Hz, 2H)3.76 (s, 2H) 3.90 (d, <i>J</i> = 6.06 Hz, 2H) 7.22–7.34 (m, 5H), 7.35–7.48)(m, 4H), 7.91 (br s, 1H).</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Receptor Functional Assays</h3><div class="NLM_p">For development of cAMP accumulation assays, recombinant IP or DP1 receptors were stably expressed in CHO-K1 cells and clonal cell lines derived following standard protocols. Receptor expression levels were minimized to preclude receptor reserve effects. HTRF cAMP assays were performed according to the manufacturer’s instructions (Cisbio, cAMP Dynamic 2 assay kit; no. 62AM4PEJ). IP receptor-expressing cells were harvested, resuspended in assay buffer (PBS containing 1 mM IBMX and 0.2% BSA) at a density of 200 000 cells per mL, and dispensed into 384-well assay plates (PerkinElmer Proxiplate no. 6008280) at 5 μL per well. Test compounds were solubilized and serially diluted in DMSO using 5-fold dilutions to generate a 10-point dose–response curve with a top concentration of 10 μM. The samples were then further diluted in PBS to achieve a 2× stock. Diluted compounds were then transferred to a triplicate set of assay plates (5 μL per well). After a 1 h incubation at room temperature, 5 μL of cAMP-D2 reagent diluted in lysis buffer was added to each well followed by 5 μL of cryptate reagent. Plates were then incubated at room temperature for 1 h prior to reading. Time-resolved fluorescence measurements were collected on PerkinElmer Envision or BMG Pherastar microplate readers.</div><div class="NLM_p last">For the EP<sub>3v6</sub> receptor functional assay, melanophores were transfected by electroporation using 20 μg of recombinant human EP<sub>3v6</sub> receptor plasmid DNA per 400 μL of cell suspension. Transfected cells were immediately resuspended in fresh growth medium and plated in 384-well clear, polystyrene microplates. Plated cells were incubated at 27 °C for 48 h after transfection in order to achieve optimal receptor expression. To perform the assay, growth medium was removed from the assay plates and replaced with assay buffer (40 μL/well, 0.7× PBS, pH 7.3, supplemented with 20 nM melatonin to induce pigment aggregation). Following a 90 min incubation at room temperature, a 650 nm absorbance reading was collected and test compounds (10 μL per well) were transferred to the assay plates. Plates were incubated for 90 min at room temperature to allow compound-induced pigment redistribution to take place, and final absorbance reading was then collected. Test compounds were solubilized and serially diluted in DMSO, using 5-fold dilutions, to generate a 10-point dose–response curve with a top concentration of 10 μM (final assay concentration). Samples were then further diluted in assay buffer to achieve a 5× stock prior to addition to the assay plates. A SpectraMax absorbance plate reader (Molecular Devices, Inc.) was used for data collection.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Radioligand Binding Assays</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Membrane Preparation</h4><div class="NLM_p last">CHO-K1 cells expressing recombinant IP receptors were harvested, washed with ice-cold phosphate buffered saline, pH 7.4 (PBS), and then centrifuged at 48 000<i>g</i> for 20 min at 4 °C. The resulting cell pellet was then resuspended in ice-cold PBS containing 20 mM HEPES, pH 7.4, and 0.1 mM EDTA, homogenized on ice using a Brinkman Polytron, and centrifuged (48 000<i>g</i> for 20 min at 4 °C). This resuspension and centrifugation process was repeated one further time. Crude membrane pellets were stored at −80 °C until used for radioligand binding assays.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Radioligand Binding Assay Protocol</h4><div class="NLM_p">Radioligand binding assays were conducted using the IP receptor agonist [<sup>3</sup>H]-iloprost as radioligand, and nonspecific binding was determined in the presence of unlabeled 10 μM iloprost. Specific assay conditions for each receptor are listed in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. Competition experiments consisted of addition of 45 μL of assay buffer (PBS containing 20 mM HEPES and 10 mM MgCl<sub>2</sub>, pH 7.4), 100 μL of membranes, 50 μL of [<sup>3</sup>H]-iloprost, and 5 μL of test compound diluted in assay buffer to 96-well microtiter plates, which were then incubated for 1 h at room temperature. Assay incubations were terminated by rapid filtration through PerkinElmer GF/C filtration plates pretreated with 0.3% PEI, under vacuum pressure using a 96-well Packard filtration apparatus, followed by multiple washes with ice-cold wash buffer (PBS containing 20 mM HEPES and 0.1 mM EDTA, pH 7.4). Plates were then dried at 45 °C for a minimum of 2 h. Finally, 25 μL of BetaScint scintillation cocktail was added to each well and plates were counted in a Packard TopCount scintillation counter. In each competition study, test compounds were dosed at 10 concentrations with triplicate determinations at each test concentration. A reference compound, typically iloprost, was included in every runset for quality control purposes.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Assay Conditions for Recombinant IP Receptor Binding Assay</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">receptor</th><th class="colsep0 rowsep0" align="center" char=".">[<sup>3</sup>H]-iloprost assay concentration (nM)</th><th class="colsep0 rowsep0" align="center" char=".">membrane protein (μg)</th><th class="colsep0 rowsep0" align="center" char=".">measured <i>K</i><sub>d</sub> (nM)</th><th class="colsep0 rowsep0" align="center">literature <i>K</i><sub>d</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human IP</td><td class="colsep0 rowsep0" align="char" char=".">7.57</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="left">9.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey IP</td><td class="colsep0 rowsep0" align="char" char=".">7.57</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog IP</td><td class="colsep0 rowsep0" align="char" char=".">7.57</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">15.4</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat IP</td><td class="colsep0 rowsep0" align="char" char=".">7.57</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table></div></div><div class="NLM_p last">Additional (non-IP) receptor binding assays were carried out by MDS Pharma (Taiwan) and CEREP (France).</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> In Vivo Assay</h3><div class="NLM_p last">All in vivo experiments were performed in accordance with the ACS ethical guidelines</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Animal Model</h3><div class="NLM_p last">In the study to evaluate the effects of oral administration of <b>5c</b> on MCT-induced PAH, we used 38 male Sprague–Dawley rats weighing 200–250 g; 30 rats were chosen randomly to receive a subcutaneous injection of 60 mg/kg MCT on day 1 of the trial, while the remaining 8 received a subcutaneous injection of saline (sham, <i>n</i> = 8). The MCT-injected rats were then assigned to one of three treatment protocols: oral treatment with <b>5c</b> from day 1 (10 and 30 mg/kg, <i>n</i> = 10 in each dose group) and oral 20% HPBCD in saline (control group, <i>n</i> = 10).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> In Vivo Experimental Protocol</h3><div class="NLM_p">Following anesthesia by intraperitoneal injection of 30 mg/kg pentobarbital, rats were given a subcutaneous injection of either 60 mg/kg MCT (Sigma, catalog no. C2401-1G) or 0.9% saline for the sham group. The following day and for 20 days thereafter, 10 mg/kg and 30 mg/kg (<b>5c</b> treatment groups, <i>n</i> = 10) or oral 20% HPBCD in saline (control group, <i>n</i> = 10) was administered twice daily by oral gavage. Hemodynamic measurements and histologic analyses were performed on day 21; this time point was based on survival curve analyses (2 animals that died on study in the control group on days 19 and 20 could not be evaluated; hence only 8 animals are included in the measurements for this group and not 10). Hemodynamic measurements were performed with animals from the 30 mg/kg group (but not the 10 mg/kg group) anesthetized with 60 mg/kg pentobarbital. Under anesthesia, each animal was intubated with a rodent ventilator (Harvard Apparatus, model 683) at 70 breaths/min of a rate and a tidal volume of 2.5 mL in supine position on a heating pad set at 37 °C. A small opening in the apex of the right ventricle was made using a 23G needle, then a Millar catheter (Millar Instruments, Inc. model SPR-320) was placed into the right ventricle through the opening in the apex, then into the pulmonary artery (PA) for the pressure measurement. A second catheter was inserted through the right jugular vein into the right ventricle (RV) for the measurement of mean arterial pressure. After stabilization, heart rate, mean arterial pressure, and systolic RV pressure were calculated from 20 consecutive heart beats in each rat. Due to the technical difficulty involved in the catheter placement, 5 animals in the 30 mg/kg treated group could not be stabilized sufficiently for measurements to be made; hence a data set of only 5 animals in the high dose group was used for the mPAP figure.</div><div class="NLM_p">The ventricles and lungs were excised and weighed. The ratio of RV weight to left ventricle plus septum (LV + S) was calculated as an index of right ventricular hypertrophy.</div><div class="NLM_p last">In a separate experiment, the same protocol was used with <b>5g</b> except that doses of 15 and 30 mg/kg were used as a result of the weak effect of <b>5c</b> on (RV/(LV + S)) at 10 mg/kg in the first experiment.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Morphometric Analysis of Pulmonary Arterioles</h3><div class="NLM_p">As the collection and preservation of the tissues are very resource intensive, 5 animals were selected from each group for measurement of vessel thickness; this was sufficient to obtain clear statistical differences between groups. Paraffin sections of 4 μm thickness were obtained from the lower region of the right lung and stained with hematoxylin/eosin. Analysis of the medial wall thickness of the pulmonary arterioles was performed. In brief, the external diameter and medial wall thickness were measured in 20 muscular arteries (25–100 μm external diameters) per lung section. For each artery, the medial wall thickness was expressed as follows: % wall thickness = [(external diameter – internal diameter)/external diameter] × 100. Each vessel was measured twice, perpendicularly along the long axis and short axis, and averages of both measurements were used.</div><div class="NLM_p last">All data are expressed as mean ± SEM. Comparisons of parameters among the three groups were made by one-way analysis of variance (ANOVA), followed by Newman–Keuls’ test. Comparisons of the time course of parameters between two groups were made by two-way ANOVA for repeated measures, followed by Newman–Keuls’ test. A value of<i>P</i> < 0.05 was considered statistically significant. Survival curves were derived by the Kaplan–Meier method and compared by log-rank test. <i>P</i> < 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00871">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00871" class="ext-link">10.1021/acs.jmedchem.6b00871</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Detailed procedures and summary data for additional in vitro assays and further data from in vivo assays for compound <b>5c</b>; DMPK profile in the cynomolgus monkey for <b>5c</b>; physical form characterization data for <b>5c</b> and <b>5g</b>; receptor binding profile of <b>5c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf">jm6b00871_si_001.pdf (1.68 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00871" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graeme Semple</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9666-1588" title="Orcid link">http://orcid.org/0000-0002-9666-1588</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#731400161e031f1633111612101c1d171a00101c0516010a5d101c1e"><span class="__cf_email__" data-cfemail="80e7f3e5edf0ece5c0e2e5e1e3efeee4e9f3e3eff6e5f2f9aee3efed">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thuy-Anh Tran</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan Kramer</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Young-Jun Shin</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pureza Vallar</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">P. Douglas Boatman</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Zou</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carleton R. Sage</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tawfik Gharbaoui</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashwin Krishnan</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Biman Pal</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sagar R. Shakya</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonio Garrido Montalban</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John W. Adams</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Ramirez</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dominic P. Behan</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Shifrina</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Blackburn</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tina Leakakos</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunqing Shi</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Morgan</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abu Sadeque</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weichao Chen</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David J. Unett</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ibragim Gaidarov</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohua Chen</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Chang</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hsin-Hui Shu</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiu-Feng Tung</span> - <span class="hlFld-Affiliation affiliation">Arena Pharmaceuticals, 6154 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i70" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i70"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i71" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i71"> Abbreviations Used</h2><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine 5′-diphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BDC</td><td class="NLM_def"><p class="first last">bile-duct cannulated</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">3′,5′-cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">3′,5′-cyclic guanosine monophosphate</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">clogP</td><td class="NLM_def"><p class="first last">calculated log <i>P</i> value</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetics</p></td></tr><tr><td class="NLM_term"><i>F</i>(sp<sup>3</sup>)</td><td class="NLM_def"><p class="first last">fraction of sp<sup>3</sup> carbon atoms</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human-ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">PAH</td><td class="NLM_def"><p class="first last">pulmonary arterial hypertension</p></td></tr><tr><td class="NLM_term">PDE5</td><td class="NLM_def"><p class="first last">phosphodiesterase-5</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">USAN</td><td class="NLM_def"><p class="first last">United States Adopted Names</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62575" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62575" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 19 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Rubanyi, G. M.</span><span> </span><span class="NLM_article-title">The role of endothelium in cardiovascular homeostasis and diseases</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 4</span><span class="NLM_x">) </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S14</span><span class="refDoi"> DOI: 10.1097/00005344-199322004-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1097%2F00005344-199322004-00002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1993&pages=S1-S14&issue=Suppl.+4&author=G.+M.+Rubanyi&title=The+role+of+endothelium+in+cardiovascular+homeostasis+and+diseases&doi=10.1097%2F00005344-199322004-00002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1097%2F00005344-199322004-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199322004-00002%26sid%3Dliteratum%253Aachs%26aulast%3DRubanyi%26aufirst%3DG.%2BM.%26atitle%3DThe%2520role%2520of%2520endothelium%2520in%2520cardiovascular%2520homeostasis%2520and%2520diseases%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1993%26volume%3D22%26issue%3DSuppl.%25204%26spage%3DS1%26epage%3DS14%26doi%3D10.1097%2F00005344-199322004-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Christman, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groves, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyd, J. E.</span><span> </span><span class="NLM_article-title">An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1056/NEJM199207093270202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1056%2FNEJM199207093270202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1603138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A280%3ADyaK383ptlaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=1992&pages=70-75&author=B.+W.+Christmanauthor=C.+D.+McPhersonauthor=J.+H.+Newmanauthor=G.+A.+Kingauthor=G.+R.+Bernardauthor=B.+M.+Grovesauthor=J.+E.+Loyd&title=An+imbalance+between+the+excretion+of+thromboxane+and+prostacyclin+metabolites+in+pulmonary+hypertension&doi=10.1056%2FNEJM199207093270202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension</span></div><div class="casAuthors">Christman B W; McPherson C D; Newman J H; King G A; Bernard G R; Groves B M; Loyd J E</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">70-5</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Constriction of small pulmonary arteries and arterioles and focal vascular injury are features of pulmonary hypertension.  Because thromboxane A2 is both a vasoconstrictor and a potent stimulus for platelet aggregation, it may be an important mediator of pulmonary hypertension.  Its effects are antagonized by prostacyclin, which is released by vascular endothelial cells.  We tested the hypothesis that there may be an imbalance between the release of thromboxane A2 and prostacyclin in pulmonary hypertension, reflecting platelet activation and an abnormal response of the pulmonary vascular endothelium.  METHODS:  We used radioimmunoassays to measure the 24-hour urinary excretion of two stable metabolites of thromboxane A2 and a metabolite of prostacyclin in 20 patients with primary pulmonary hypertension, 14 with secondary pulmonary hypertension, 9 with severe chronic obstructive pulmonary disease (COPD) but no clinical evidence of pulmonary hypertension, and 23 normal controls.  RESULTS:  The 24-hour excretion of 11-dehydro-thromboxane B2 (a stable metabolite of thromboxane A2) was increased in patients with primary pulmonary hypertension and patients with secondary pulmonary hypertension, as compared with normal controls (3224 +/- 482, 5392 +/- 1640, and 1145 +/- 221 pg per milligram of creatinine, respectively; P less than 0.05), whereas the 24-hour excretion of 2,3-dinor-6-keto-prostaglandin F1 alpha (a stable metabolite of prostacyclin) was decreased (369 +/- 106, 304 +/- 76, and 644 +/- 124 pg per milligram of creatinine, respectively; P less than 0.05).  The rate of excretion of all metabolites in the patients with COPD but no clinical evidence of pulmonary hypertension was similar to that in the normal controls.  CONCLUSIONS:  An increase in the release of the vasoconstrictor thromboxane A2, suggesting the activation of platelets, occurs in both the primary and secondary forms of pulmonary hypertension.  By contrast, the release of prostacyclin is depressed in these patients.  Whether the imbalance in the release of these mediators is a cause or a result of pulmonary hypertension is unknown, but it may play a part in the development and maintenance of both forms of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlWhhWOTLoiJI8NvIb08rbfW6udTcc2eboAKMDh1Jsf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383ptlaksA%253D%253D&md5=6a3cc537453ec1dcaa9220dbbbe4d51d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJM199207093270202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199207093270202%26sid%3Dliteratum%253Aachs%26aulast%3DChristman%26aufirst%3DB.%2BW.%26aulast%3DMcPherson%26aufirst%3DC.%2BD.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26aulast%3DKing%26aufirst%3DG.%2BA.%26aulast%3DBernard%26aufirst%3DG.%2BR.%26aulast%3DGroves%26aufirst%3DB.%2BM.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26atitle%3DAn%2520imbalance%2520between%2520the%2520excretion%2520of%2520thromboxane%2520and%2520prostacyclin%2520metabolites%2520in%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D327%26spage%3D70%26epage%3D75%26doi%3D10.1056%2FNEJM199207093270202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Rich, S.</span><span> </span><span class="NLM_article-title">Clinical insights into the pathogenesis of primary pulmonary hypertension</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">237S</span><span class="NLM_x">–</span> <span class="NLM_lpage">241S</span><span class="refDoi"> DOI: 10.1378/chest.114.3_Supplement.237S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1378%2Fchest.114.3_Supplement.237S" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1998&pages=237S-241S&author=S.+Rich&title=Clinical+insights+into+the+pathogenesis+of+primary+pulmonary+hypertension&doi=10.1378%2Fchest.114.3_Supplement.237S"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1378%2Fchest.114.3_Supplement.237S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.114.3_Supplement.237S%26sid%3Dliteratum%253Aachs%26aulast%3DRich%26aufirst%3DS.%26atitle%3DClinical%2520insights%2520into%2520the%2520pathogenesis%2520of%2520primary%2520pulmonary%2520hypertension%26jtitle%3DChest%26date%3D1998%26volume%3D114%26spage%3D237S%26epage%3D241S%26doi%3D10.1378%2Fchest.114.3_Supplement.237S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groves, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frosolono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cato, A. E.</span><span> </span><span class="NLM_article-title">Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.1161/01.CIR.66.2.334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1161%2F01.CIR.66.2.334" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1982&pages=334-338&author=L.+J.+Rubinauthor=B.+M.+Grovesauthor=J.+T.+Reevesauthor=M.+Frosolonoauthor=F.+Handelauthor=A.+E.+Cato&title=Prostacyclin-induced+acute+pulmonary+vasodilation+in+primary+pulmonary+hypertension&doi=10.1161%2F01.CIR.66.2.334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.66.2.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.66.2.334%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DGroves%26aufirst%3DB.%2BM.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DFrosolono%26aufirst%3DM.%26aulast%3DHandel%26aufirst%3DF.%26aulast%3DCato%26aufirst%3DA.%2BE.%26atitle%3DProstacyclin-induced%2520acute%2520pulmonary%2520vasodilation%2520in%2520primary%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D1982%26volume%3D66%26spage%3D334%26epage%3D338%26doi%3D10.1161%2F01.CIR.66.2.334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Provencher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granton, J. T.</span><span> </span><span class="NLM_article-title">Current treatment approaches to Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Can. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1016/j.cjca.2014.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.cjca.2014.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=25840096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A280%3ADC%252BC2MfksVOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2015&pages=460-477&author=S.+Provencherauthor=T.+Johnauthor=J.+T.+Granton&title=Current+treatment+approaches+to+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.cjca.2014.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current treatment approaches to pulmonary arterial hypertension</span></div><div class="casAuthors">Provencher Steeve; Granton John T</div><div class="citationInfo"><span class="NLM_cas:title">The Canadian journal of cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">460-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Because of the complexities of the disease, early recognition and referral of patients with pulmonary arterial hypertension (PAH) to an expert centre is critically important.  Advances in our understanding of the pathogenesis of PAH have translated into novel treatment strategies and pharmacotherapies.  A supervised rehabilitation program, psychosocial support, and referral to palliative care might lead to improvements in exercise capacity and quality of life.  At present the current medical treatments include prostanoids (parenteral, oral, and inhaled), endothelin antagonists, and agents that increase nitric oxide bioavailability.  Although these agents all cause pulmonary vasodilation, they have been shown to improve outcome in patients who do not demonstrate an acute vasodilatory response.  This suggests that they might also alter the abnormal proliferative vasculopathy that characterizes PAH.  These agents have variably led to improvements in exercise capacity, symptoms, hemodynamics, and markers of right ventricular dysfunction.  Adopting the principles of a goal-directed approach, most practitioners (and guidelines) advocate sequentially adding treatments until patients achieve a satisfactory clinical response.  Emerging data suggest that upfront combination therapy might be superior to monotherapy.  For patients who fail to achieve a satisfactory clinical response, parenteral prostanoids remain the medical treatment of choice.  Early referral for evaluation of lung transplantation should be considered for patients who continue to demonstrate poor prognostic features or who require advanced medical treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAvoo1O0luClZoq0fPSOTvfW6udTcc2ebld70jFuYEVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfksVOhsQ%253D%253D&md5=10942064465127fcc096e06f87b903b2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cjca.2014.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cjca.2014.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DGranton%26aufirst%3DJ.%2BT.%26atitle%3DCurrent%2520treatment%2520approaches%2520to%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2015%26volume%3D31%26spage%3D460%26epage%3D477%26doi%3D10.1016%2Fj.cjca.2014.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hellawell, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farber, H. W.</span><span> </span><span class="NLM_article-title">Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1517/17425255.2014.958466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1517%2F17425255.2014.958466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=25204984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOrtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1445-1453&author=J.+L.+Hellawellauthor=S.+Bhattacharyaauthor=H.+W.+Farber&title=Pharmacokinetic+evaluation+of+treprostinil+%28oral%29+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1517%2F17425255.2014.958466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic evaluation of (oral) for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Hellawell, Jennifer L.; Bhattacharya, Sanjeeb; Farber, Harrison W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1445-1453</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: This review summarizes current information on the first oral prostanoid approved for treatment of pulmonary arterial hypertension, , which, similar to other prostacyclin analogs, vasodilates, impacts remodeling (antiproliferative), reduces endothelial cell dysfunction, inhibits platelet aggregation (antithrombotic) and increases right heart inotropy.  Areas covered: From a pharmacol. point of view, it appears that with sustained blood concns. for 8 - 10 h after a single dose, twice or thrice daily dosing is possible.  This review discusses three randomized trials of oral treprostinil that have been completed (FREEDOM-M, FREEDOM-C, FREEDOM-C2).  FREEDOM-C and -C2 evaluated oral treprostinil in patients on stable background therapy; FREEDOM-M evaluated oral treprostinil as monotherapy.  In FREEDOM-M, the primary end point (6-min walk distance; 6MWD) was attained, but was not reached in either FREEDOM-C trial.  As such, the FDA did not grant approval.  Thus, another clin. trial (FREEDOM-EV) is underway: oral treprostinil in patients on background therapy evaluating co-primary end points: i) change in 6MWD; and ii) occurrence of predetd. events.  In the interim, oral treprostinil was approved in Dec. 2013.  Expert opinion: The use and future of oral treprostinil is not clear.  This will depend on the ability to titrate the drug to high levels with acceptable tolerance, on the results of FREEDOM-EV trial and on the impact of selexipag and other oral prostanoids being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6da_1-Fhsp7Vg90H21EOLACvtfcHk0ljyu91LCoiYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOrtrbJ&md5=f79800f62a4c011b9ec4cb3ede39519b</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.958466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.958466%26sid%3Dliteratum%253Aachs%26aulast%3DHellawell%26aufirst%3DJ.%2BL.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DFarber%26aufirst%3DH.%2BW.%26atitle%3DPharmacokinetic%2520evaluation%2520of%2520treprostinil%2520%2528oral%2529%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26spage%3D1445%26epage%3D1453%26doi%3D10.1517%2F17425255.2014.958466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bruderer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects</span> <span class="citation_source-journal">Pharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1159/000367630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1159%2F000367630" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=148-156&author=S.+Brudererauthor=N.+Hurstauthor=P.+Kaufmannauthor=J.+Dingemanse&title=Multiple-dose+up-titration+study+to+evaluate+the+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+selexipag%2C+an+orally+available+selective+prostacyclin+receptor+agonist%2C+in+healthy+subjects&doi=10.1159%2F000367630"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1159%2F000367630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000367630%26sid%3Dliteratum%253Aachs%26aulast%3DBruderer%26aufirst%3DS.%26aulast%3DHurst%26aufirst%3DN.%26aulast%3DKaufmann%26aufirst%3DP.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DMultiple-dose%2520up-titration%2520study%2520to%2520evaluate%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520selexipag%252C%2520an%2520orally%2520available%2520selective%2520prostacyclin%2520receptor%2520agonist%252C%2520in%2520healthy%2520subjects%26jtitle%3DPharmacology%26date%3D2014%26volume%3D94%26spage%3D148%26epage%3D156%26doi%3D10.1159%2F000367630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Morrison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1124/jpet.110.169748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1124%2Fjpet.110.169748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=20660124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1GisrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=249-255&author=K.+Morrisonauthor=R.+Ernstauthor=P.+Hessauthor=R.+Studerauthor=M.+Clozel&title=Selexipag%3A+a+selective+prostacyclin+receptor+agonist+that+does+not+affect+rat+gastric+function&doi=10.1124%2Fjpet.110.169748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function</span></div><div class="casAuthors">Morrison, Keith; Ernst, Roland; Hess, Patrick; Studer, Rolf; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI2) receptor (IP receptor) agonist that is chem. distinct from PGI2 and is in clin. development for the treatment of pulmonary arterial hypertension.  Selexipag is highly selective for the human IP receptor in vitro, whereas analogs of PGI2 can activate prostanoid receptors other than the IP receptor.  The goal of this study was to det. the impact of selectivity for the IP receptor on gastric function by measuring 1) contraction of rat gastric fundus ex vivo and 2) the rates of gastric emptying and intestinal transport in response to selexipag in comparison with other PGI2 analogs.  The rat gastric fundus expresses mRNA encoding multiple prostanoid receptors to different levels: prostaglandin E receptor 1 (EP1) > prostaglandin E receptor 3 (EP3), IP receptor > prostaglandin D2 receptor 1, thromboxane receptor.  Selexipag and metabolite {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) did not contract gastric fundus at concns. up to 10-3 M.  In contrast, the PGI2 analogs iloprost and beraprost evoked concn.-dependent contraction of gastric fundus.  Contraction to treprostinil was obsd. at high concn. (10-4 M).  Contraction to all PGI2 analogs was mediated via activation of EP3 receptors, although EP1 receptors also contributed to the contraction of gastric fundus to iloprost and beraprost.  Antagonism of IP receptors did not affect responses.  Oral selexipag did not significantly alter gastric function in vivo, as measured by rates of stomach emptying and intestinal transport, whereas beraprost slowed gastrointestinal transport.  The high functional selectivity of selexipag and ACT-333679 for the IP receptor precludes a stimulatory action on gastric smooth muscle and may help minimize gastric side effects such as nausea and vomiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq03Bb9GH0xabVg90H21EOLACvtfcHk0lgjnlMhIWQyAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1GisrvK&md5=f17239c0e4c62c768c1cc1d8dcd7f4ca</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.169748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.169748%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DErnst%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DSelexipag%253A%2520a%2520selective%2520prostacyclin%2520receptor%2520agonist%2520that%2520does%2520not%2520affect%2520rat%2520gastric%2520function%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D249%26epage%3D255%26doi%3D10.1124%2Fjpet.110.169748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unett, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span> </span><span class="NLM_article-title">Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1030</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.bmcl.2015.01.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1030-1035&author=T.+Tranauthor=Y.-J.+Shinauthor=B.+Kramerauthor=J.+Choiauthor=N.+Zouauthor=P.+Vallarauthor=P.+Martensauthor=P.+D.+Boatmanauthor=J.+W.+Adamsauthor=J.+Ramirezauthor=Y.+Shiauthor=M.+Morganauthor=D.+J.+Unettauthor=S.+Changauthor=H.+Shuauthor=S.+Tungauthor=G.+Semple&title=Discovery+of+a+new+series+of+potent+prostacyclin+receptor+agonists+with+in+vivo+activity+in+rat&doi=10.1016%2Fj.bmcl.2015.01.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DN.%26aulast%3DVallar%26aufirst%3DP.%26aulast%3DMartens%26aufirst%3DP.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DH.%26aulast%3DTung%26aufirst%3DS.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520new%2520series%2520of%2520potent%2520prostacyclin%2520receptor%2520agonists%2520with%2520in%2520vivo%2520activity%2520in%2520rat%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1030%26epage%3D1035%26doi%3D10.1016%2Fj.bmcl.2015.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gomez-Arroyo, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farkas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alhussaini, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farkas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraskauskas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voelkel, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaard, H. J.</span><span> </span><span class="NLM_article-title">The monocrotaline model of pulmonary hypertension in perspective</span> <span class="citation_source-journal">Am. J. Physiol. Lung Cell Mol. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">L363</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span><span class="refDoi"> DOI: 10.1152/ajplung.00212.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1152%2Fajplung.00212.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=21964406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsFKns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2012&pages=L363-369&author=J.+G.+Gomez-Arroyoauthor=L.+Farkasauthor=A.+A.+Alhussainiauthor=D.+Farkasauthor=D.+Kraskauskasauthor=N.+F.+Voelkelauthor=H.+J.+Bogaard&title=The+monocrotaline+model+of+pulmonary+hypertension+in+perspective&doi=10.1152%2Fajplung.00212.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The monocrotaline model of pulmonary hypertension in perspective</span></div><div class="casAuthors">Gomez-Arroyo, Jose G.; Farkas, Laszlo; Alhussaini, Aysar A.; Farkas, Daniela; Kraskauskas, Donatas; Voelkel, Norbert F.; Bogaard, Harm J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">L363-L369</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Severe forms of pulmonary arterial hypertension (PAH) are characterized by various degrees of remodeling of the pulmonary arterial vessels, which increases the pulmonary vascular resistance and right ventricular afterload, thus contributing to the development of right ventricle dysfunction and failure.  Recent years have seen advances in the understanding of the pathobiol. of PAH; however, many important questions remain unanswered.  Elucidating the pathobiol. of PAH continues to be crit. to design new effective therapeutic strategies, and appropriate animal models of PAH are necessary to achieve the task.  Although the monocrotaline rat model of PAH has contributed to a better understanding of vascular remodeling in pulmonary hypertension, we question the validity of this model as a preclinically relevant model of severe plexogenic PAH.  Here we review pertinent publications that either have been forgotten or ignored, and we reexamine the monocrotaline model in the context of human forms of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfhQAJlfdHW7Vg90H21EOLACvtfcHk0lgjnlMhIWQyAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsFKns78%253D&md5=bc1f51b0ed2a5a71e02974c1e51a0474</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00212.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00212.2011%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Arroyo%26aufirst%3DJ.%2BG.%26aulast%3DFarkas%26aufirst%3DL.%26aulast%3DAlhussaini%26aufirst%3DA.%2BA.%26aulast%3DFarkas%26aufirst%3DD.%26aulast%3DKraskauskas%26aufirst%3DD.%26aulast%3DVoelkel%26aufirst%3DN.%2BF.%26aulast%3DBogaard%26aufirst%3DH.%2BJ.%26atitle%3DThe%2520monocrotaline%2520model%2520of%2520pulmonary%2520hypertension%2520in%2520perspective%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2012%26volume%3D302%26spage%3DL363%26epage%3D369%26doi%3D10.1152%2Fajplung.00212.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0li2A-KpPv4I8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability+%E2%80%93+are+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0li2A-KpPv4I8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%2520%25E2%2580%2593%2520are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Nakamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7720</span><span class="NLM_x">–</span> <span class="NLM_lpage">7725</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.bmc.2007.08.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=17881233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7720-7725&author=A.+Nakamuraauthor=T.+Yamadaauthor=T.+Asaki&title=Synthesis+and+evaluation+of+N-acylsulfonamide+and+N-acylsulfonylurea+prodrugs+of+a+prostacyclin+receptor+agonist&doi=10.1016%2Fj.bmc.2007.08.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span></div><div class="casAuthors">Nakamura, Akio; Yamada, Tetsuhiro; Asaki, Tetsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7720-7725</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">N-Acylsulfonamide and N-acylsulfonylurea derivs. of the carboxylic acid prostacyclin receptor agonist 1 (I) were synthesized and their potential as prodrug forms of the carboxylic acid was evaluated in vitro and in vivo.  These compds. were converted to the active compd. 1 by hepatic microsomes from rats, dogs, monkeys, and humans, and some of the compds. were shown to yield sustained plasma concns. of 1 when they were orally administered to monkeys.  These types of analogs, including NS-304 (2a), are potentially useful prodrugs of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3pafmMVkL07Vg90H21EOLACvtfcHk0li2A-KpPv4I8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF&md5=e48076b73d0c2bd9b4312dab5e0693ad</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DAsaki%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-acylsulfonamide%2520and%2520N-acylsulfonylurea%2520prodrugs%2520of%2520a%2520prostacyclin%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7720%26epage%3D7725%26doi%3D10.1016%2Fj.bmc.2007.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Galiè, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branzi, A.</span><span> </span><span class="NLM_article-title">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1049</span><span class="refDoi"> DOI: 10.1183/09031936.02.05542002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1183%2F09031936.02.05542002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=12412701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1037-1049&author=N.+Gali%C3%A8author=A.+Manesauthor=A.+Branzi&title=The+new+clinical+trials+on+pharmacological+treatment+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.02.05542002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Manes, A.; Branzi, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1049</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive subjects and oral anti-coagulants and continuous i.v. administration of epoprostenol in the more severe cases.  Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogs treprostinil, beraprost and iloprost, and the endothelin receptor antagonist bosentan have been tested in clin. trials in >1,100 patients.  Except for terbogrel, all compds. improved the mean exercise capacity by different degrees, as assessed by the 6-min walk test.  In the evaluation of the clin. relevance of exercise capacity improvements, addnl. elements need to be considered, such as baseline functional class and concomitant favorable effects on combined clin. events (including hospitalizations, mortality and rescue therapies), quality of life and hemodynamics.  No trials have shown effects on mortality, as the study protocols were not designed for assessing this end-point.  Each new compd. presents side-effects that are unpredictable in the individual patient and require appropriate attention upon treatment initiation and maintenance.  These new therapeutic options will be available in the near future and will allow tailoring of the most appropriate treatment to the single patient, according to an individualized benefit-to-risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4jEc_GhfAP7Vg90H21EOLACvtfcHk0li2A-KpPv4I8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D&md5=40c0c3940d3ff20dd629afd5db22e416</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.05542002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.05542002%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DBranzi%26aufirst%3DA.%26atitle%3DThe%2520new%2520clinical%2520trials%2520on%2520pharmacological%2520treatment%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D20%26spage%3D1037%26epage%3D1049%26doi%3D10.1183%2F09031936.02.05542002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Adams, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teegarden, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span> </span><span class="NLM_article-title">Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">586</span><span class="NLM_x">, </span> <span class="NLM_fpage">234</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2007.11.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.ejphar.2007.11.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=18358471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVGmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=586&publication_year=2008&pages=234-243&author=J.+W.+Adamsauthor=J.+Ramirezauthor=D.+Ortunoauthor=Y.+Shiauthor=W.+Thomsenauthor=J.+G.+Richmanauthor=M.+Morganauthor=P.+Dosaauthor=B.+R.+Teegardenauthor=H.+Al-Shammaauthor=D.+P.+Behanauthor=D.+T.+Connolly&title=Anti-thrombotic+and+vascular+effects+of+AR246686%2C+a+novel+5-HT2A+receptor+antagonist&doi=10.1016%2Fj.ejphar.2007.11.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist</span></div><div class="casAuthors">Adams, John W.; Ramirez, Juan; Ortuno, Danny; Shi, Yunqing; Thomsen, William; Richman, Jeremy G.; Morgan, Michael; Dosa, Peter; Teegarden, Bradley R.; Al-Shamma, Hussien; Behan, Dominic P.; Connolly, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">586</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">234-243</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have evaluated the anti-platelet and vascular pharmacol. of AR246686, a novel 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist.  AR246686 displayed high affinity binding to membranes of HEK cells stably expressing recombinant human and rat 5-HT2A receptors (K i = 0.2 nM and 0.4 nM, resp.).  Functional antagonism (IC50 = 1.9 nM) with AR246686 was detd. by inhibition of ligand-independent inositol phosphate accumulation in the 5-HT2A stable cell line.  We obsd. 8.7-fold and 1360-fold higher affinity of AR246686 for the 5-HT2A receptor vs. 5-HT2C and 5-HT2B receptors, resp.  AR246686 inhibited 5-HT-induced amplification of ADP-stimulated human platelet aggregation (IC50 = 21 nM).  Similar potency was obsd. for inhibition of 5-HT stimulated DNA synthesis in rat aortic smooth muscle cells (IC50 = 10 nM) and 5-HT-mediated contraction in rat aortic rings.  Effects of AR246686 on arterial thrombosis and bleeding time were studied in a rat model of femoral artery occlusion.  Oral dosing of AR246686 to rats resulted in prolongation of time to occlusion at 1 mg/kg, whereas increased bleeding time was obsd. at a dose of 20 mg/kg.  In contrast, both bleeding time and time to occlusion were increased at the same dose (10 mg/kg) of clopidogrel.  These results demonstrate that AR246686 is a high affinity 5-HT2A receptor antagonist with potent activity on platelets and vascular smooth muscle.  Further, oral administration results in anti-thrombotic effects at doses that are free of significant effects on traumatic bleeding time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx-q6Rhj4A2LVg90H21EOLACvtfcHk0lhnOmOz7h3qMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVGmt7c%253D&md5=55a5ebb3cbd556cc8ba440a55aa12380</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2007.11.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2007.11.056%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DOrtuno%26aufirst%3DD.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DW.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DDosa%26aufirst%3DP.%26aulast%3DTeegarden%26aufirst%3DB.%2BR.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26atitle%3DAnti-thrombotic%2520and%2520vascular%2520effects%2520of%2520AR246686%252C%2520a%2520novel%25205-HT2A%2520receptor%2520antagonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D586%26spage%3D234%26epage%3D243%26doi%3D10.1016%2Fj.ejphar.2007.11.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="note"><p class="first last">95 GPCR profile (MDS Pharma Inc.).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Way, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayawickreme, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenakin, T.</span><span> </span><span class="NLM_article-title">Use of constitutive G protein-coupled receptor activity for drug discovery</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=125-134&author=G.+Chenauthor=J.+Wayauthor=S.+Armourauthor=C.+Watsonauthor=K.+Queenauthor=C.+K.+Jayawickremeauthor=W.+J.+Chenauthor=T.+Kenakin&title=Use+of+constitutive+G+protein-coupled+receptor+activity+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWay%26aufirst%3DJ.%26aulast%3DArmour%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DQueen%26aufirst%3DK.%26aulast%3DJayawickreme%26aufirst%3DC.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BJ.%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DUse%2520of%2520constitutive%2520G%2520protein-coupled%2520receptor%2520activity%2520for%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapp, L.</span><span> </span><span class="NLM_article-title">APD811, a novel and highly selective non-prostanoid IP receptor agonist in smooth muscle cells from patients with pulmonary hypertension</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">A16601</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2016&pages=A16601&author=L.+Shenauthor=J.+Patelauthor=D.+B.+Behanauthor=J.+W.+Adamsauthor=L.+Clapp&title=APD811%2C+a+novel+and+highly+selective+non-prostanoid+IP+receptor+agonist+in+smooth+muscle+cells+from+patients+with+pulmonary+hypertension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DBehan%26aufirst%3DD.%2BB.%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DClapp%26aufirst%3DL.%26atitle%3DAPD811%252C%2520a%2520novel%2520and%2520highly%2520selective%2520non-prostanoid%2520IP%2520receptor%2520agonist%2520in%2520smooth%2520muscle%2520cells%2520from%2520patients%2520with%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2016%26volume%3D134%26spage%3DA16601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="note"><p class="first last"><b>5c</b> and all related compounds are highly potent APIs and can cause cutaneous vasodilation following skin exposure. It is also possible that they may cause significant systemic hypotension if swallowed or inhaled. Full PPE precautions were taken and breathing apparatus was used during the conversion of <b>9</b> to <b>5c</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rudolph, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloeters-Plachky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stiehl, A.</span><span> </span><span class="NLM_article-title">Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate</span> <span class="citation_source-journal">Eur. J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1046/j.1365-2362.2002.01030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1046%2Fj.1365-2362.2002.01030.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=575-580&author=G.+Rudolphauthor=P.+Kloeters-Plachkyauthor=P.+Sauerauthor=A.+Stiehl&title=Intestinal+absorption+and+biliary+secretion+of+ursodeoxycholic+acid+and+its+taurine+conjugate&doi=10.1046%2Fj.1365-2362.2002.01030.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2362.2002.01030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2362.2002.01030.x%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DG.%26aulast%3DKloeters-Plachky%26aufirst%3DP.%26aulast%3DSauer%26aufirst%3DP.%26aulast%3DStiehl%26aufirst%3DA.%26atitle%3DIntestinal%2520absorption%2520and%2520biliary%2520secretion%2520of%2520ursodeoxycholic%2520acid%2520and%2520its%2520taurine%2520conjugate%26jtitle%3DEur.%2520J.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D32%26spage%3D575%26epage%3D580%26doi%3D10.1046%2Fj.1365-2362.2002.01030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':[],'ref16':['cit16'],'ref17':['cit17'],'ref18':[],'ref19':['cit19']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wei Zheng, Zhen Wang, Xiangrui Jiang, Qingjie Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Jingshan Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15153-15186. <a href="https://doi.org/10.1021/acs.jmedchem.0c01093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BDrugs%252Bfor%252BTreatment%252Bof%252BPulmonary%252BArterial%252BHypertension%25253A%252BPast%25252C%252BPresent%25252C%252Band%252BFuture%252BPerspectives%26aulast%3DZheng%26aufirst%3DWei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26062020%26date%3D14122020%26volume%3D63%26issue%3D24%26spage%3D15153%26epage%3D15186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongzhao  Wang</span>, <span class="hlFld-ContribAuthor ">Zijian  Qin</span>, <span class="hlFld-ContribAuthor ">Aixia  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>69 </em><a href="https://doi.org/10.1007/s11030-020-10165-4" title="DOI URL">https://doi.org/10.1007/s11030-020-10165-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10165-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10165-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DClassification%252Bmodels%252Band%252BSAR%252Banalysis%252Bon%252BCysLT1%252Breceptor%252Bantagonists%252Busing%252Bmachine%252Blearning%252Balgorithms%26aulast%3DWang%26aufirst%3DHongzhao%26date%3D2021%26date%3D2021%26volume%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John S.  Grundy</span>, <span class="hlFld-ContribAuthor ">Christopher D.  King</span>, <span class="hlFld-ContribAuthor ">John W.  Adams</span>, <span class="hlFld-ContribAuthor ">Christopher H.  Cabell</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers. </span><span class="cited-content_cbyCitation_journal-name">Pulmonary Circulation</span><span> <strong>2020,</strong> <em>10 </em>
                                    (2)
                                     , 204589402092281. <a href="https://doi.org/10.1177/2045894020922814" title="DOI URL">https://doi.org/10.1177/2045894020922814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2045894020922814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2045894020922814%26sid%3Dliteratum%253Aachs%26jtitle%3DPulmonary%2520Circulation%26atitle%3DSafety%25252C%252Btolerability%25252C%252Band%252Bpharmacokinetics%252Bof%252Bthe%252Bselective%252Bprostacyclin%252Breceptor%252Bagonist%252Bralinepag%252Bin%252Bsingle%252Band%252Bmultiple%252Bdosing%252Bstudies%252Bof%252Ban%252Bimmediate-release%252Boral%252Bformulation%252Bin%252Bhealthy%252Bvolunteers%26aulast%3DGrundy%26aufirst%3DJohn%2BS.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D2%26spage%3D204589402092281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucie H.  Clapp</span>, <span class="hlFld-ContribAuthor ">Jeries H. J.  Abu-Hanna</span>, <span class="hlFld-ContribAuthor ">Jigisha A.  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 31-61. <a href="https://doi.org/10.1007/978-981-15-1185-1_5" title="DOI URL">https://doi.org/10.1007/978-981-15-1185-1_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-1185-1_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-1185-1_5%26sid%3Dliteratum%253Aachs%26atitle%3DDiverse%252BPharmacology%252Bof%252BProstacyclin%252BMimetics%25253A%252BImplications%252Bfor%252BPulmonary%252BHypertension%26aulast%3DClapp%26aufirst%3DLucie%2BH.%26date%3D2020%26date%3D2020%26spage%3D31%26epage%3D61%26pub%3DSpringer%2520Singapore%26atitle%3DMolecular%252BMechanism%252Bof%252BCongenital%252BHeart%252BDisease%252Band%252BPulmonary%252BHypertension%26aulast%3DNakanishi%26aufirst%3DToshio%26date%3D2020%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fernando  Torres</span>, <span class="hlFld-ContribAuthor ">Harrison  Farber</span>, <span class="hlFld-ContribAuthor ">Arsen  Ristic</span>, <span class="hlFld-ContribAuthor ">Vallerie  McLaughlin</span>, <span class="hlFld-ContribAuthor ">John  Adams</span>, <span class="hlFld-ContribAuthor ">Jinkun  Zhang</span>, <span class="hlFld-ContribAuthor ">Preston  Klassen</span>, <span class="hlFld-ContribAuthor ">William  Shanahan</span>, <span class="hlFld-ContribAuthor ">John  Grundy</span>, <span class="hlFld-ContribAuthor ">Ines  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Christopher  Cabell</span>, <span class="hlFld-ContribAuthor ">Pilar  Escribano Subías</span>, <span class="hlFld-ContribAuthor ">Namita  Sood</span>, <span class="hlFld-ContribAuthor ">Anne  Keogh</span>, <span class="hlFld-ContribAuthor ">Gwyn  D'Souza</span>, <span class="hlFld-ContribAuthor ">Lewis  Rubin</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. </span><span class="cited-content_cbyCitation_journal-name">European Respiratory Journal</span><span> <strong>2019,</strong> <em>54 </em>
                                    (4)
                                     , 1901030. <a href="https://doi.org/10.1183/13993003.01030-2019" title="DOI URL">https://doi.org/10.1183/13993003.01030-2019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1183/13993003.01030-2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1183%2F13993003.01030-2019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Respiratory%2520Journal%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252Bralinepag%25252C%252Ba%252Bnovel%252Boral%252BIP%252Bagonist%25252C%252Bin%252BPAH%252Bpatients%252Bon%252Bmono%252Bor%252Bdual%252Bbackground%252Btherapy%25253A%252Bresults%252Bfrom%252Ba%252Bphase%252B2%252Brandomised%25252C%252Bparallel%252Bgroup%25252C%252Bplacebo-controlled%252Btrial%26aulast%3DTorres%26aufirst%3DFernando%26date%3D2019%26date%3D2019%26volume%3D54%26issue%3D4%26spage%3D1901030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selexipag and its active metabolite.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Simplification approach to redesign of prostacyclin agonist series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Library Route for the Preparation of the Cyclohexyl Scaffold/Carbamate Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) R<sup>1</sup>PhNCO, pyridine; (ii) <i>tert</i>-butyl diazoacetate, (Rh(OAc)<sub>2</sub>)<sub>2</sub>; (iii) R<sup>2</sup>I, CuI, K<sub>3</sub>PO<sub>4</sub>, microwave; (iv) HCl, dioxane.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Larger Scale Syntheses of the Cyclohexyl Scaffold/Carbamate Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method 1: [R<sup>1</sup> = 4-Cl or 3-F, R<sup>2</sup> = H] (i) [R<sup>2</sup> = 3-F] PhBr, KO<i><sup>t</sup></i>Bu, Pd(dppf)Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, toluene; (ii) triphosgene, pyridine, 0 °C; (iii) [X = Cl] (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol, pyridine, heat; (iv) <i>tert</i>-butyl diazoacetate, (Rh(OAc)<sub>2</sub>)<sub>2</sub> (v) HCl, dioxane. Method 2: [R<sup>1</sup> = 4-Cl, R<sup>2</sup> = H] (ii) carbonyldiimidazole, acetonitrile, K<sub>3</sub>PO<sub>4</sub>; (iii) [X = 1-imidazole] (1<i>r</i>,4<i>r</i>)-cyclohexane-1,4-diyldimethanol (4 equiv), acetonitrile, 65 °C (68–78% two steps); (iv) ethyl bromoacetate, tetrabutylammonium bromide, 50% NaOH, toluene; (v) (a) heat; (b) HCl (62–67% two steps).</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of <b>5c</b> in the MCT model after oral administration. MCT = monocrotaline; Veh = vehicle; RV/(LV + S) = ratio of right ventricle weight to weight of left ventricle plus septum, an index of right ventricular hypertrophy (<i>n</i> = 8 for sham, <i>n</i> = 8 for MCT + veh group and <i>n</i> = 10 for <b>5c</b> treatment groups); mPAP = mean pulmonary arterial pressure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Preparation of M1 Metabolite<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) thionyl chloride; (b) taurine, 20% NaOH, 0 °C.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/medium/jm-2016-00871j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Metabolite profile of <b>5c</b> in the rat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b00871/20170203/images/large/jm-2016-00871j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00871&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 19 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Rubanyi, G. M.</span><span> </span><span class="NLM_article-title">The role of endothelium in cardiovascular homeostasis and diseases</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 4</span><span class="NLM_x">) </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S14</span><span class="refDoi"> DOI: 10.1097/00005344-199322004-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1097%2F00005344-199322004-00002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1993&pages=S1-S14&issue=Suppl.+4&author=G.+M.+Rubanyi&title=The+role+of+endothelium+in+cardiovascular+homeostasis+and+diseases&doi=10.1097%2F00005344-199322004-00002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1097%2F00005344-199322004-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199322004-00002%26sid%3Dliteratum%253Aachs%26aulast%3DRubanyi%26aufirst%3DG.%2BM.%26atitle%3DThe%2520role%2520of%2520endothelium%2520in%2520cardiovascular%2520homeostasis%2520and%2520diseases%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1993%26volume%3D22%26issue%3DSuppl.%25204%26spage%3DS1%26epage%3DS14%26doi%3D10.1097%2F00005344-199322004-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Christman, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groves, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyd, J. E.</span><span> </span><span class="NLM_article-title">An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1056/NEJM199207093270202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1056%2FNEJM199207093270202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1603138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A280%3ADyaK383ptlaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=1992&pages=70-75&author=B.+W.+Christmanauthor=C.+D.+McPhersonauthor=J.+H.+Newmanauthor=G.+A.+Kingauthor=G.+R.+Bernardauthor=B.+M.+Grovesauthor=J.+E.+Loyd&title=An+imbalance+between+the+excretion+of+thromboxane+and+prostacyclin+metabolites+in+pulmonary+hypertension&doi=10.1056%2FNEJM199207093270202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension</span></div><div class="casAuthors">Christman B W; McPherson C D; Newman J H; King G A; Bernard G R; Groves B M; Loyd J E</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">70-5</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Constriction of small pulmonary arteries and arterioles and focal vascular injury are features of pulmonary hypertension.  Because thromboxane A2 is both a vasoconstrictor and a potent stimulus for platelet aggregation, it may be an important mediator of pulmonary hypertension.  Its effects are antagonized by prostacyclin, which is released by vascular endothelial cells.  We tested the hypothesis that there may be an imbalance between the release of thromboxane A2 and prostacyclin in pulmonary hypertension, reflecting platelet activation and an abnormal response of the pulmonary vascular endothelium.  METHODS:  We used radioimmunoassays to measure the 24-hour urinary excretion of two stable metabolites of thromboxane A2 and a metabolite of prostacyclin in 20 patients with primary pulmonary hypertension, 14 with secondary pulmonary hypertension, 9 with severe chronic obstructive pulmonary disease (COPD) but no clinical evidence of pulmonary hypertension, and 23 normal controls.  RESULTS:  The 24-hour excretion of 11-dehydro-thromboxane B2 (a stable metabolite of thromboxane A2) was increased in patients with primary pulmonary hypertension and patients with secondary pulmonary hypertension, as compared with normal controls (3224 +/- 482, 5392 +/- 1640, and 1145 +/- 221 pg per milligram of creatinine, respectively; P less than 0.05), whereas the 24-hour excretion of 2,3-dinor-6-keto-prostaglandin F1 alpha (a stable metabolite of prostacyclin) was decreased (369 +/- 106, 304 +/- 76, and 644 +/- 124 pg per milligram of creatinine, respectively; P less than 0.05).  The rate of excretion of all metabolites in the patients with COPD but no clinical evidence of pulmonary hypertension was similar to that in the normal controls.  CONCLUSIONS:  An increase in the release of the vasoconstrictor thromboxane A2, suggesting the activation of platelets, occurs in both the primary and secondary forms of pulmonary hypertension.  By contrast, the release of prostacyclin is depressed in these patients.  Whether the imbalance in the release of these mediators is a cause or a result of pulmonary hypertension is unknown, but it may play a part in the development and maintenance of both forms of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlWhhWOTLoiJI8NvIb08rbfW6udTcc2eY62qh5yrMrXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383ptlaksA%253D%253D&md5=6a3cc537453ec1dcaa9220dbbbe4d51d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJM199207093270202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199207093270202%26sid%3Dliteratum%253Aachs%26aulast%3DChristman%26aufirst%3DB.%2BW.%26aulast%3DMcPherson%26aufirst%3DC.%2BD.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26aulast%3DKing%26aufirst%3DG.%2BA.%26aulast%3DBernard%26aufirst%3DG.%2BR.%26aulast%3DGroves%26aufirst%3DB.%2BM.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26atitle%3DAn%2520imbalance%2520between%2520the%2520excretion%2520of%2520thromboxane%2520and%2520prostacyclin%2520metabolites%2520in%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D327%26spage%3D70%26epage%3D75%26doi%3D10.1056%2FNEJM199207093270202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Rich, S.</span><span> </span><span class="NLM_article-title">Clinical insights into the pathogenesis of primary pulmonary hypertension</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">237S</span><span class="NLM_x">–</span> <span class="NLM_lpage">241S</span><span class="refDoi"> DOI: 10.1378/chest.114.3_Supplement.237S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1378%2Fchest.114.3_Supplement.237S" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1998&pages=237S-241S&author=S.+Rich&title=Clinical+insights+into+the+pathogenesis+of+primary+pulmonary+hypertension&doi=10.1378%2Fchest.114.3_Supplement.237S"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1378%2Fchest.114.3_Supplement.237S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.114.3_Supplement.237S%26sid%3Dliteratum%253Aachs%26aulast%3DRich%26aufirst%3DS.%26atitle%3DClinical%2520insights%2520into%2520the%2520pathogenesis%2520of%2520primary%2520pulmonary%2520hypertension%26jtitle%3DChest%26date%3D1998%26volume%3D114%26spage%3D237S%26epage%3D241S%26doi%3D10.1378%2Fchest.114.3_Supplement.237S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groves, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frosolono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cato, A. E.</span><span> </span><span class="NLM_article-title">Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.1161/01.CIR.66.2.334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1161%2F01.CIR.66.2.334" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1982&pages=334-338&author=L.+J.+Rubinauthor=B.+M.+Grovesauthor=J.+T.+Reevesauthor=M.+Frosolonoauthor=F.+Handelauthor=A.+E.+Cato&title=Prostacyclin-induced+acute+pulmonary+vasodilation+in+primary+pulmonary+hypertension&doi=10.1161%2F01.CIR.66.2.334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.66.2.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.66.2.334%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DGroves%26aufirst%3DB.%2BM.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DFrosolono%26aufirst%3DM.%26aulast%3DHandel%26aufirst%3DF.%26aulast%3DCato%26aufirst%3DA.%2BE.%26atitle%3DProstacyclin-induced%2520acute%2520pulmonary%2520vasodilation%2520in%2520primary%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D1982%26volume%3D66%26spage%3D334%26epage%3D338%26doi%3D10.1161%2F01.CIR.66.2.334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Provencher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granton, J. T.</span><span> </span><span class="NLM_article-title">Current treatment approaches to Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Can. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1016/j.cjca.2014.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.cjca.2014.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=25840096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A280%3ADC%252BC2MfksVOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2015&pages=460-477&author=S.+Provencherauthor=T.+Johnauthor=J.+T.+Granton&title=Current+treatment+approaches+to+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.cjca.2014.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current treatment approaches to pulmonary arterial hypertension</span></div><div class="casAuthors">Provencher Steeve; Granton John T</div><div class="citationInfo"><span class="NLM_cas:title">The Canadian journal of cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">460-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Because of the complexities of the disease, early recognition and referral of patients with pulmonary arterial hypertension (PAH) to an expert centre is critically important.  Advances in our understanding of the pathogenesis of PAH have translated into novel treatment strategies and pharmacotherapies.  A supervised rehabilitation program, psychosocial support, and referral to palliative care might lead to improvements in exercise capacity and quality of life.  At present the current medical treatments include prostanoids (parenteral, oral, and inhaled), endothelin antagonists, and agents that increase nitric oxide bioavailability.  Although these agents all cause pulmonary vasodilation, they have been shown to improve outcome in patients who do not demonstrate an acute vasodilatory response.  This suggests that they might also alter the abnormal proliferative vasculopathy that characterizes PAH.  These agents have variably led to improvements in exercise capacity, symptoms, hemodynamics, and markers of right ventricular dysfunction.  Adopting the principles of a goal-directed approach, most practitioners (and guidelines) advocate sequentially adding treatments until patients achieve a satisfactory clinical response.  Emerging data suggest that upfront combination therapy might be superior to monotherapy.  For patients who fail to achieve a satisfactory clinical response, parenteral prostanoids remain the medical treatment of choice.  Early referral for evaluation of lung transplantation should be considered for patients who continue to demonstrate poor prognostic features or who require advanced medical treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAvoo1O0luClZoq0fPSOTvfW6udTcc2eb0eYOtON5i4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfksVOhsQ%253D%253D&md5=10942064465127fcc096e06f87b903b2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cjca.2014.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cjca.2014.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DGranton%26aufirst%3DJ.%2BT.%26atitle%3DCurrent%2520treatment%2520approaches%2520to%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2015%26volume%3D31%26spage%3D460%26epage%3D477%26doi%3D10.1016%2Fj.cjca.2014.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hellawell, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farber, H. W.</span><span> </span><span class="NLM_article-title">Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1517/17425255.2014.958466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1517%2F17425255.2014.958466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=25204984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOrtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1445-1453&author=J.+L.+Hellawellauthor=S.+Bhattacharyaauthor=H.+W.+Farber&title=Pharmacokinetic+evaluation+of+treprostinil+%28oral%29+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1517%2F17425255.2014.958466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic evaluation of (oral) for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Hellawell, Jennifer L.; Bhattacharya, Sanjeeb; Farber, Harrison W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1445-1453</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: This review summarizes current information on the first oral prostanoid approved for treatment of pulmonary arterial hypertension, , which, similar to other prostacyclin analogs, vasodilates, impacts remodeling (antiproliferative), reduces endothelial cell dysfunction, inhibits platelet aggregation (antithrombotic) and increases right heart inotropy.  Areas covered: From a pharmacol. point of view, it appears that with sustained blood concns. for 8 - 10 h after a single dose, twice or thrice daily dosing is possible.  This review discusses three randomized trials of oral treprostinil that have been completed (FREEDOM-M, FREEDOM-C, FREEDOM-C2).  FREEDOM-C and -C2 evaluated oral treprostinil in patients on stable background therapy; FREEDOM-M evaluated oral treprostinil as monotherapy.  In FREEDOM-M, the primary end point (6-min walk distance; 6MWD) was attained, but was not reached in either FREEDOM-C trial.  As such, the FDA did not grant approval.  Thus, another clin. trial (FREEDOM-EV) is underway: oral treprostinil in patients on background therapy evaluating co-primary end points: i) change in 6MWD; and ii) occurrence of predetd. events.  In the interim, oral treprostinil was approved in Dec. 2013.  Expert opinion: The use and future of oral treprostinil is not clear.  This will depend on the ability to titrate the drug to high levels with acceptable tolerance, on the results of FREEDOM-EV trial and on the impact of selexipag and other oral prostanoids being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6da_1-Fhsp7Vg90H21EOLACvtfcHk0lhLUAobKYCj_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOrtrbJ&md5=f79800f62a4c011b9ec4cb3ede39519b</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.958466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.958466%26sid%3Dliteratum%253Aachs%26aulast%3DHellawell%26aufirst%3DJ.%2BL.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DFarber%26aufirst%3DH.%2BW.%26atitle%3DPharmacokinetic%2520evaluation%2520of%2520treprostinil%2520%2528oral%2529%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26spage%3D1445%26epage%3D1453%26doi%3D10.1517%2F17425255.2014.958466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bruderer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects</span> <span class="citation_source-journal">Pharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1159/000367630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1159%2F000367630" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=148-156&author=S.+Brudererauthor=N.+Hurstauthor=P.+Kaufmannauthor=J.+Dingemanse&title=Multiple-dose+up-titration+study+to+evaluate+the+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+selexipag%2C+an+orally+available+selective+prostacyclin+receptor+agonist%2C+in+healthy+subjects&doi=10.1159%2F000367630"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1159%2F000367630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000367630%26sid%3Dliteratum%253Aachs%26aulast%3DBruderer%26aufirst%3DS.%26aulast%3DHurst%26aufirst%3DN.%26aulast%3DKaufmann%26aufirst%3DP.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DMultiple-dose%2520up-titration%2520study%2520to%2520evaluate%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520selexipag%252C%2520an%2520orally%2520available%2520selective%2520prostacyclin%2520receptor%2520agonist%252C%2520in%2520healthy%2520subjects%26jtitle%3DPharmacology%26date%3D2014%26volume%3D94%26spage%3D148%26epage%3D156%26doi%3D10.1159%2F000367630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Morrison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1124/jpet.110.169748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1124%2Fjpet.110.169748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=20660124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1GisrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=249-255&author=K.+Morrisonauthor=R.+Ernstauthor=P.+Hessauthor=R.+Studerauthor=M.+Clozel&title=Selexipag%3A+a+selective+prostacyclin+receptor+agonist+that+does+not+affect+rat+gastric+function&doi=10.1124%2Fjpet.110.169748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function</span></div><div class="casAuthors">Morrison, Keith; Ernst, Roland; Hess, Patrick; Studer, Rolf; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI2) receptor (IP receptor) agonist that is chem. distinct from PGI2 and is in clin. development for the treatment of pulmonary arterial hypertension.  Selexipag is highly selective for the human IP receptor in vitro, whereas analogs of PGI2 can activate prostanoid receptors other than the IP receptor.  The goal of this study was to det. the impact of selectivity for the IP receptor on gastric function by measuring 1) contraction of rat gastric fundus ex vivo and 2) the rates of gastric emptying and intestinal transport in response to selexipag in comparison with other PGI2 analogs.  The rat gastric fundus expresses mRNA encoding multiple prostanoid receptors to different levels: prostaglandin E receptor 1 (EP1) > prostaglandin E receptor 3 (EP3), IP receptor > prostaglandin D2 receptor 1, thromboxane receptor.  Selexipag and metabolite {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) did not contract gastric fundus at concns. up to 10-3 M.  In contrast, the PGI2 analogs iloprost and beraprost evoked concn.-dependent contraction of gastric fundus.  Contraction to treprostinil was obsd. at high concn. (10-4 M).  Contraction to all PGI2 analogs was mediated via activation of EP3 receptors, although EP1 receptors also contributed to the contraction of gastric fundus to iloprost and beraprost.  Antagonism of IP receptors did not affect responses.  Oral selexipag did not significantly alter gastric function in vivo, as measured by rates of stomach emptying and intestinal transport, whereas beraprost slowed gastrointestinal transport.  The high functional selectivity of selexipag and ACT-333679 for the IP receptor precludes a stimulatory action on gastric smooth muscle and may help minimize gastric side effects such as nausea and vomiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq03Bb9GH0xabVg90H21EOLACvtfcHk0lhLUAobKYCj_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1GisrvK&md5=f17239c0e4c62c768c1cc1d8dcd7f4ca</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.169748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.169748%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DErnst%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DSelexipag%253A%2520a%2520selective%2520prostacyclin%2520receptor%2520agonist%2520that%2520does%2520not%2520affect%2520rat%2520gastric%2520function%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D249%26epage%3D255%26doi%3D10.1124%2Fjpet.110.169748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unett, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span> </span><span class="NLM_article-title">Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1030</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.bmcl.2015.01.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1030-1035&author=T.+Tranauthor=Y.-J.+Shinauthor=B.+Kramerauthor=J.+Choiauthor=N.+Zouauthor=P.+Vallarauthor=P.+Martensauthor=P.+D.+Boatmanauthor=J.+W.+Adamsauthor=J.+Ramirezauthor=Y.+Shiauthor=M.+Morganauthor=D.+J.+Unettauthor=S.+Changauthor=H.+Shuauthor=S.+Tungauthor=G.+Semple&title=Discovery+of+a+new+series+of+potent+prostacyclin+receptor+agonists+with+in+vivo+activity+in+rat&doi=10.1016%2Fj.bmcl.2015.01.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DN.%26aulast%3DVallar%26aufirst%3DP.%26aulast%3DMartens%26aufirst%3DP.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DH.%26aulast%3DTung%26aufirst%3DS.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520new%2520series%2520of%2520potent%2520prostacyclin%2520receptor%2520agonists%2520with%2520in%2520vivo%2520activity%2520in%2520rat%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1030%26epage%3D1035%26doi%3D10.1016%2Fj.bmcl.2015.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gomez-Arroyo, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farkas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alhussaini, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farkas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraskauskas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voelkel, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaard, H. J.</span><span> </span><span class="NLM_article-title">The monocrotaline model of pulmonary hypertension in perspective</span> <span class="citation_source-journal">Am. J. Physiol. Lung Cell Mol. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">L363</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span><span class="refDoi"> DOI: 10.1152/ajplung.00212.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1152%2Fajplung.00212.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=21964406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsFKns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2012&pages=L363-369&author=J.+G.+Gomez-Arroyoauthor=L.+Farkasauthor=A.+A.+Alhussainiauthor=D.+Farkasauthor=D.+Kraskauskasauthor=N.+F.+Voelkelauthor=H.+J.+Bogaard&title=The+monocrotaline+model+of+pulmonary+hypertension+in+perspective&doi=10.1152%2Fajplung.00212.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The monocrotaline model of pulmonary hypertension in perspective</span></div><div class="casAuthors">Gomez-Arroyo, Jose G.; Farkas, Laszlo; Alhussaini, Aysar A.; Farkas, Daniela; Kraskauskas, Donatas; Voelkel, Norbert F.; Bogaard, Harm J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">L363-L369</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Severe forms of pulmonary arterial hypertension (PAH) are characterized by various degrees of remodeling of the pulmonary arterial vessels, which increases the pulmonary vascular resistance and right ventricular afterload, thus contributing to the development of right ventricle dysfunction and failure.  Recent years have seen advances in the understanding of the pathobiol. of PAH; however, many important questions remain unanswered.  Elucidating the pathobiol. of PAH continues to be crit. to design new effective therapeutic strategies, and appropriate animal models of PAH are necessary to achieve the task.  Although the monocrotaline rat model of PAH has contributed to a better understanding of vascular remodeling in pulmonary hypertension, we question the validity of this model as a preclinically relevant model of severe plexogenic PAH.  Here we review pertinent publications that either have been forgotten or ignored, and we reexamine the monocrotaline model in the context of human forms of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfhQAJlfdHW7Vg90H21EOLACvtfcHk0ljWrWiltphXwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsFKns78%253D&md5=bc1f51b0ed2a5a71e02974c1e51a0474</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00212.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00212.2011%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Arroyo%26aufirst%3DJ.%2BG.%26aulast%3DFarkas%26aufirst%3DL.%26aulast%3DAlhussaini%26aufirst%3DA.%2BA.%26aulast%3DFarkas%26aufirst%3DD.%26aulast%3DKraskauskas%26aufirst%3DD.%26aulast%3DVoelkel%26aufirst%3DN.%2BF.%26aulast%3DBogaard%26aufirst%3DH.%2BJ.%26atitle%3DThe%2520monocrotaline%2520model%2520of%2520pulmonary%2520hypertension%2520in%2520perspective%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2012%26volume%3D302%26spage%3DL363%26epage%3D369%26doi%3D10.1152%2Fajplung.00212.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljWrWiltphXwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability+%E2%80%93+are+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0liSOXzcxUf1GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%2520%25E2%2580%2593%2520are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Nakamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7720</span><span class="NLM_x">–</span> <span class="NLM_lpage">7725</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.bmc.2007.08.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=17881233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7720-7725&author=A.+Nakamuraauthor=T.+Yamadaauthor=T.+Asaki&title=Synthesis+and+evaluation+of+N-acylsulfonamide+and+N-acylsulfonylurea+prodrugs+of+a+prostacyclin+receptor+agonist&doi=10.1016%2Fj.bmc.2007.08.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span></div><div class="casAuthors">Nakamura, Akio; Yamada, Tetsuhiro; Asaki, Tetsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7720-7725</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">N-Acylsulfonamide and N-acylsulfonylurea derivs. of the carboxylic acid prostacyclin receptor agonist 1 (I) were synthesized and their potential as prodrug forms of the carboxylic acid was evaluated in vitro and in vivo.  These compds. were converted to the active compd. 1 by hepatic microsomes from rats, dogs, monkeys, and humans, and some of the compds. were shown to yield sustained plasma concns. of 1 when they were orally administered to monkeys.  These types of analogs, including NS-304 (2a), are potentially useful prodrugs of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3pafmMVkL07Vg90H21EOLACvtfcHk0liSOXzcxUf1GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF&md5=e48076b73d0c2bd9b4312dab5e0693ad</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DAsaki%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-acylsulfonamide%2520and%2520N-acylsulfonylurea%2520prodrugs%2520of%2520a%2520prostacyclin%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7720%26epage%3D7725%26doi%3D10.1016%2Fj.bmc.2007.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Galiè, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branzi, A.</span><span> </span><span class="NLM_article-title">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1049</span><span class="refDoi"> DOI: 10.1183/09031936.02.05542002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1183%2F09031936.02.05542002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=12412701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1037-1049&author=N.+Gali%C3%A8author=A.+Manesauthor=A.+Branzi&title=The+new+clinical+trials+on+pharmacological+treatment+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.02.05542002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Manes, A.; Branzi, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1049</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive subjects and oral anti-coagulants and continuous i.v. administration of epoprostenol in the more severe cases.  Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogs treprostinil, beraprost and iloprost, and the endothelin receptor antagonist bosentan have been tested in clin. trials in >1,100 patients.  Except for terbogrel, all compds. improved the mean exercise capacity by different degrees, as assessed by the 6-min walk test.  In the evaluation of the clin. relevance of exercise capacity improvements, addnl. elements need to be considered, such as baseline functional class and concomitant favorable effects on combined clin. events (including hospitalizations, mortality and rescue therapies), quality of life and hemodynamics.  No trials have shown effects on mortality, as the study protocols were not designed for assessing this end-point.  Each new compd. presents side-effects that are unpredictable in the individual patient and require appropriate attention upon treatment initiation and maintenance.  These new therapeutic options will be available in the near future and will allow tailoring of the most appropriate treatment to the single patient, according to an individualized benefit-to-risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4jEc_GhfAP7Vg90H21EOLACvtfcHk0liSOXzcxUf1GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D&md5=40c0c3940d3ff20dd629afd5db22e416</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.05542002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.05542002%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DBranzi%26aufirst%3DA.%26atitle%3DThe%2520new%2520clinical%2520trials%2520on%2520pharmacological%2520treatment%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D20%26spage%3D1037%26epage%3D1049%26doi%3D10.1183%2F09031936.02.05542002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Adams, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teegarden, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span> </span><span class="NLM_article-title">Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">586</span><span class="NLM_x">, </span> <span class="NLM_fpage">234</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2007.11.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1016%2Fj.ejphar.2007.11.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=18358471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVGmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=586&publication_year=2008&pages=234-243&author=J.+W.+Adamsauthor=J.+Ramirezauthor=D.+Ortunoauthor=Y.+Shiauthor=W.+Thomsenauthor=J.+G.+Richmanauthor=M.+Morganauthor=P.+Dosaauthor=B.+R.+Teegardenauthor=H.+Al-Shammaauthor=D.+P.+Behanauthor=D.+T.+Connolly&title=Anti-thrombotic+and+vascular+effects+of+AR246686%2C+a+novel+5-HT2A+receptor+antagonist&doi=10.1016%2Fj.ejphar.2007.11.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist</span></div><div class="casAuthors">Adams, John W.; Ramirez, Juan; Ortuno, Danny; Shi, Yunqing; Thomsen, William; Richman, Jeremy G.; Morgan, Michael; Dosa, Peter; Teegarden, Bradley R.; Al-Shamma, Hussien; Behan, Dominic P.; Connolly, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">586</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">234-243</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have evaluated the anti-platelet and vascular pharmacol. of AR246686, a novel 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist.  AR246686 displayed high affinity binding to membranes of HEK cells stably expressing recombinant human and rat 5-HT2A receptors (K i = 0.2 nM and 0.4 nM, resp.).  Functional antagonism (IC50 = 1.9 nM) with AR246686 was detd. by inhibition of ligand-independent inositol phosphate accumulation in the 5-HT2A stable cell line.  We obsd. 8.7-fold and 1360-fold higher affinity of AR246686 for the 5-HT2A receptor vs. 5-HT2C and 5-HT2B receptors, resp.  AR246686 inhibited 5-HT-induced amplification of ADP-stimulated human platelet aggregation (IC50 = 21 nM).  Similar potency was obsd. for inhibition of 5-HT stimulated DNA synthesis in rat aortic smooth muscle cells (IC50 = 10 nM) and 5-HT-mediated contraction in rat aortic rings.  Effects of AR246686 on arterial thrombosis and bleeding time were studied in a rat model of femoral artery occlusion.  Oral dosing of AR246686 to rats resulted in prolongation of time to occlusion at 1 mg/kg, whereas increased bleeding time was obsd. at a dose of 20 mg/kg.  In contrast, both bleeding time and time to occlusion were increased at the same dose (10 mg/kg) of clopidogrel.  These results demonstrate that AR246686 is a high affinity 5-HT2A receptor antagonist with potent activity on platelets and vascular smooth muscle.  Further, oral administration results in anti-thrombotic effects at doses that are free of significant effects on traumatic bleeding time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx-q6Rhj4A2LVg90H21EOLACvtfcHk0ljY72AllWd4EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVGmt7c%253D&md5=55a5ebb3cbd556cc8ba440a55aa12380</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2007.11.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2007.11.056%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DOrtuno%26aufirst%3DD.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DW.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DDosa%26aufirst%3DP.%26aulast%3DTeegarden%26aufirst%3DB.%2BR.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26atitle%3DAnti-thrombotic%2520and%2520vascular%2520effects%2520of%2520AR246686%252C%2520a%2520novel%25205-HT2A%2520receptor%2520antagonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D586%26spage%3D234%26epage%3D243%26doi%3D10.1016%2Fj.ejphar.2007.11.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="note"><p class="first last">95 GPCR profile (MDS Pharma Inc.).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Way, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayawickreme, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenakin, T.</span><span> </span><span class="NLM_article-title">Use of constitutive G protein-coupled receptor activity for drug discovery</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=125-134&author=G.+Chenauthor=J.+Wayauthor=S.+Armourauthor=C.+Watsonauthor=K.+Queenauthor=C.+K.+Jayawickremeauthor=W.+J.+Chenauthor=T.+Kenakin&title=Use+of+constitutive+G+protein-coupled+receptor+activity+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWay%26aufirst%3DJ.%26aulast%3DArmour%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DQueen%26aufirst%3DK.%26aulast%3DJayawickreme%26aufirst%3DC.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BJ.%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DUse%2520of%2520constitutive%2520G%2520protein-coupled%2520receptor%2520activity%2520for%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapp, L.</span><span> </span><span class="NLM_article-title">APD811, a novel and highly selective non-prostanoid IP receptor agonist in smooth muscle cells from patients with pulmonary hypertension</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">A16601</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2016&pages=A16601&author=L.+Shenauthor=J.+Patelauthor=D.+B.+Behanauthor=J.+W.+Adamsauthor=L.+Clapp&title=APD811%2C+a+novel+and+highly+selective+non-prostanoid+IP+receptor+agonist+in+smooth+muscle+cells+from+patients+with+pulmonary+hypertension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DBehan%26aufirst%3DD.%2BB.%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DClapp%26aufirst%3DL.%26atitle%3DAPD811%252C%2520a%2520novel%2520and%2520highly%2520selective%2520non-prostanoid%2520IP%2520receptor%2520agonist%2520in%2520smooth%2520muscle%2520cells%2520from%2520patients%2520with%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2016%26volume%3D134%26spage%3DA16601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="note"><p class="first last"><b>5c</b> and all related compounds are highly potent APIs and can cause cutaneous vasodilation following skin exposure. It is also possible that they may cause significant systemic hypotension if swallowed or inhaled. Full PPE precautions were taken and breathing apparatus was used during the conversion of <b>9</b> to <b>5c</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rudolph, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloeters-Plachky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stiehl, A.</span><span> </span><span class="NLM_article-title">Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate</span> <span class="citation_source-journal">Eur. J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1046/j.1365-2362.2002.01030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;key=10.1046%2Fj.1365-2362.2002.01030.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=575-580&author=G.+Rudolphauthor=P.+Kloeters-Plachkyauthor=P.+Sauerauthor=A.+Stiehl&title=Intestinal+absorption+and+biliary+secretion+of+ursodeoxycholic+acid+and+its+taurine+conjugate&doi=10.1046%2Fj.1365-2362.2002.01030.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2362.2002.01030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2362.2002.01030.x%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DG.%26aulast%3DKloeters-Plachky%26aufirst%3DP.%26aulast%3DSauer%26aufirst%3DP.%26aulast%3DStiehl%26aufirst%3DA.%26atitle%3DIntestinal%2520absorption%2520and%2520biliary%2520secretion%2520of%2520ursodeoxycholic%2520acid%2520and%2520its%2520taurine%2520conjugate%26jtitle%3DEur.%2520J.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D32%26spage%3D575%26epage%3D580%26doi%3D10.1046%2Fj.1365-2362.2002.01030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i69"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00871">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_53055"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00871">10.1021/acs.jmedchem.6b00871</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Detailed procedures and summary data for additional in vitro assays and further data from in vivo assays for compound <b>5c</b>; DMPK profile in the cynomolgus monkey for <b>5c</b>; physical form characterization data for <b>5c</b> and <b>5g</b>; receptor binding profile of <b>5c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00871/suppl_file/jm6b00871_si_001.pdf">jm6b00871_si_001.pdf (1.68 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-3%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00871%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00871" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                725KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b12888f83cca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
